Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  06-Jul-2022A Phase [ADDRESS_103037]: V116  1
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC, RAHWAY , NJ, [LOCATION_003] (MSD) .
This protocol amendment is applicable only to [LOCATION_009].
Protocol Title: A Phase 3 Clinical Study to Evaluate the Safety, To lerability, and 
Immunogenicity of V116 in Pneumococcal Vaccine -Experienced Adults 50 Years of Age or
Older
Protocol Number: 006-02
Compound Number: V116
Sponsor Name:
[CONTACT_19519] & Dohme LLC
(hereafter called the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_103038], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
IND [ADDRESS_103039] 2021- 006679- 41
Approval Date: [ADDRESS_103040]: V116  2
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_93285].
Typed Name:
[CONTACT_1641]:Date
08J3TW
PRODUCT :V116  3
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103041] :V116  4
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 02
Overall Rationale for the Amendments:
The reason for this amendment is to update the country -specific requirements for [LOCATION_009].
Summary of Changes Table:
Section # and Name [CONTACT_9353] 10.7. 2Country -
specific Requirements for 
[LOCATION_009] (Section 5.2 and 
Section 6.5)Added a [LOCATION_009] -specific version of 
exclusion criteria and restricted 
concomitant therapy.To include country -specific timeframe sfor prior and 
concomitant therapy.
Section 10.7. 2 Coun try-
specific Requirements for 
[LOCATION_009] (Section 5.2)Added a [LOCATION_009] -specific version of 
exclusion criteriaTo clarify the exclusion criteria for protected populations .
Section 10.7. 2Country -
specific Requirements for 
[LOCATION_009] (Section 10.5.2)Added a [LOCATION_009] -specific version of 
contraception requirements for female 
participants.To clarify current contraception me thods allowed during 
the study .
Section 6.[ADDRESS_103042]: V116  5
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 12
1.1 Synopsis ................................................................................................................. 12
1.2 Schema .................................................................................................................. 17
1.3 Schedule of Activities........................................................................................... 18
2 INTRODUCTION .......................................................................................................... 21
2.1 Study Rationale ....................................................................................................21
2.2 Background .......................................................................................................... 22
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 22
2.2.2 Information on Other Study -related Therapy .............................................. 23
[IP_ADDRESS] PCV15 ................................................................................................ 23
[IP_ADDRESS] PPSV23 .............................................................................................. 23
[IP_ADDRESS] Pneumococcal Vaccination Guidelines .............................................. 24
2.3 Benefit/Risk Assessment ...................................................................................... 24
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 25
4 STUDY DESIGN ............................................................................................................ 27
4.1 Overall Design ......................................................................................................27
4.2 Scientific Rationale for Study Design ................................................................ .28
4.2.1 Rationale for Endpoints ............................................................................... 28
[IP_ADDRESS] Immunogenicity Endpoints ................................................................ 28
[IP_ADDRESS] Safety Endpoints ................................................................................ 29
[IP_ADDRESS] Future Biomedical Research .............................................................. 29
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 30
4.3 Justification for Dose ........................................................................................... 30
4.4 Beginning and End -of-Study Definition ............................................................ 30
4.4.1 Clinical Criteria for Early Study Termination ............................................. 31
5 STUDY POPULATION ................................................................................................ 31
5.1 Inclusion Criteria ................................................................................................ .31
5.2 Exclusion Criteria ................................................................................................ 33
5.3 Lifestyle Considerations ...................................................................................... 34
5.4 Screen Failures .....................................................................................................34
5.5 Participant Replacement Strategy ......................................................................35
6 STUDY INTERVENTION ............................................................................................ 35
6.1 Study Intervention(s) Administered ...................................................................[ADDRESS_103043]: V116  6
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
6.1.1 Medical Devices ........................................................................................... 38
6.2 Preparation/Handling/Storage/Accountability ................................................. 38
6.2.1 Dose Preparation .......................................................................................... 38
6.2.2 Handling, Storage, and Accountability ........................................................ 38
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. [ADDRESS_103044] to Follow -up................................................................................................ .42
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 42
8.1 Administrative and General Procedures ........................................................... 44
8.1.1 Informed Consent ......................................................................................... 44
[IP_ADDRESS] General Informed Consent ................................................................ .44
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 44
[IP_ADDRESS] Consent and Collection of Specimens for Optional Assay 
Development ...................................................................................... 44
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_103045] .....................................................................45
8.1.4 Medical History ........................................................................................... 45
8.1.5 Prior and Concomitant Medications Review ............................................... 45
[IP_ADDRESS] Prior Medications ............................................................................... 45
[IP_ADDRESS] Concomitant Medications ..................................................................46
8.1.6 Assignment of Screening Number ............................................................... 46
8.1.7 Assignment of Treatment/Randomization Number .....................................46
8.1.8 Study Intervention Administration .............................................................. 46
[IP_ADDRESS] Timing of Dose Administration ......................................................... [ADDRESS_103046]: V116  7
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103047] Questionnaire ................................................................ 47
8.1.11 Discontinuation and Withdrawal ................................................................ .47
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 48
8.1.12 Participant Blinding/Unblinding ..................................................................48
8.1.13 Calibration of Equipment ............................................................................. 49
8.2 Immunogenicity Assessments ............................................................................. 49
8.2.1 Multiplex Opsonophagocytic Assay ............................................................ 49
8.2.2 Pneumococcal Electrochemiluminescence Assay .......................................50
8.3 Safety As sessments ............................................................................................... 50
8.3.1 Physical Examinations ................................................................................. 50
8.3.2 Pregnancy Testing ........................................................................................ 51
8.3.3 Body Temperature Measurement ................................................................ .51
8.3.4 Postvaccinati on Observation Period ............................................................ 51
8.3.5 Clinical Safety Laboratory Assessments ..................................................... 51
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events .................................................................................................................... 52
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 52
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......54
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...54
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 54
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 55
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_103048] ............................................................................ 55
8.4.8 Medical Device and Drug -device Combination Products -
PQCs/Malfunctions ...................................................................................... 55
8.4.9 Adverse Events on the VRC ........................................................................56
[IP_ADDRESS] Solicited Adverse Event .....................................................................56
[IP_ADDRESS] Unsolicited Adverse Events ............................................................... [ADDRESS_103049]: V116  8
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
8.12.1 Screening ...................................................................................................... 57
8.12.2 Treatment Period/Vaccination Visit ............................................................ 57
9 STATISTICAL ANALYSIS PLAN ............................................................................. 58
9.1 Statistical Analysis Plan Summary .....................................................................58
9.2 Responsibility for Analyses/In -house Blinding ................................................. 59
9.3 Hypotheses/Estimation ........................................................................................ 59
9.4 Analysis Endpoints ............................................................................................... 59
9.4.1 Immunogenicity Endpoints .......................................................................... 60
9.4.2 Safety Endpoints .......................................................................................... 61
9.5 Analysis Populations ............................................................................................ 61
9.5.1 Immunogenicity Analysis Populations ........................................................ 61
9.5.2 Safety Analysis Populations ........................................................................62
9.6 Statistical Methods ............................................................................................... 62
9.6.1 Statistical Methods for Immunogenicity Analyses ......................................63
9.6.2 Statistical Methods for Safety Anal yses ...................................................... 64
[IP_ADDRESS] Overall Safety Assessment ................................................................ 64
9.6.3 Demographic and Baseline Characteristics ................................................. 65
9.7 Interim Analyses ..................................................................................................65
9.8 Multiplicity ........................................................................................................... 66
9.9 Sample Size and Power Calculations ................................................................ .66
9.9.1 Sample Size and Power for Immunogenicity Analyses ............................... 66
9.9.2 Sample Size and Power for Safety Analyses ............................................... 67
9.10 Subgroup Analyses ............................................................................................... 68
9.11 Compliance (Medication Adherence) ................................................................ .68
9.12 Extent of Exposure ............................................................................................... 68
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS .....................................................................................................69
10.1 Appendix 1: Regulatory, Ethica l, and Study Oversight Considerations ........[ADDRESS_103050] for Clinical Trials ............................................................. 69
10.1.2 Financial Disclosure ..................................................................................... 71
10.1.3 Data Protection ............................................................................................. 72
[IP_ADDRESS] Confidentiality of Data ......................................................................72
[IP_ADDRESS] Confidentiality of Participant Records ............................................... 72
[IP_ADDRESS] Confidentiality of IRB/IEC Information ............................................ 72
10.1.4 Committees Structure ................................................................................... 73
[IP_ADDRESS] Executive Oversight Committee ........................................................ 73
[IP_ADDRESS] External Data Monitoring Committee ............................................... 73
[IP_ADDRESS] Scientific Advisory Committee (SAC) .............................................. [ADDRESS_103051]: V116  9
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.1.5 Publication Policy ........................................................................................ 73
10.1.6 Compliance with Study Registration and Results Posting Requirements ...74
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 74
10.1.8 Data Quality Assurance ............................................................................... 75
10.1.9 Source Documents ....................................................................................... 75
10.1.10 Study and Site Closure ................................................................................. 76
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 77
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 78
10.3.1 Definitions of Medication Error, Misuse, and Abuse ..................................78
10.3.2 Definition of AE .......................................................................................... 78
10.3.3 Definition of SAE ........................................................................................ 79
10.3.4 Additional Events Reported ......................................................................... 81
10.3.5 Recording AE and SAE ............................................................................... 81
10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................86
10.4 Appendix 4: Medical Device and Drug -device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up.............................................................................................................. 88
10.4.1 Definitions ....................................................................................................88
10.4.2 Recording, Assessing Causality, and Follow- up of PQCs/Malfunctions ....89
10.5 Appendix 5: Contraceptive Guidance ................................................................ 91
10.5.1 Definitions ....................................................................................................91
10.5.2 Contraception Requirements ........................................................................92
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 93
10.7 Appendix 7: Country -specific Requirements .................................................... 98
10.7.1 Country- specific Requirements for Japan .................................................... 98
10.7.2 Country- specific Requirements for [LOCATION_009] ................................................ 100
10.8 Appendix 8: Abbreviations ............................................................................... [ADDRESS_103052]: V116  10
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103053] OF TABLES
Table 1 Study Interventions .................................................................................... 36
Table 2 Approximate Blood Volumes Drawn by [CONTACT_93286] ........................................................................................................... 43
Table 3 Reporting Tim e Periods and Time Frames for Adverse Events and 
Other Reportable Safety Events ................................................................ .53
Table 4 Solicited Adverse Events ........................................................................... 56
Table 5 Analysis Strategy for Immunogenicity Variables ......................................64
Table 6 Analysis Strategy for Safety Parameters .................................................... 65
Table 7 Within -group 95% CIs for Varying Hypoth etical OPA GMTs and 
Varying Standard Deviations .....................................................................[ADDRESS_103054]: V116  11
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103055]: V116  12
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and 
Immunogenicity of V116 in Pneumococcal Vaccine -Experienced Adults 50 Years of Age or 
Older
Short Title: Safety and Immunogenicity of V116 in Vaccine -Experienced Adults
Acronym: STRIDE -6
Hypotheses, Objectives ,and Endpoints :
There is no hypothesis testing in this study .
Objectives and endpoints will be evaluated in pneumococcal vaccine -experienced adults 
≥50years of age , and will be evaluated separately within each vaccination group in each of 
the following cohorts :
Cohort 1 (prior PPSV23) :randomized to receive V116 or PCV15
Cohort 2 (prior PCV13) : randomized to re ceive V116 orPPSV23
Cohort 3 (prior PCV13+PPSV23, PCV15+PPSV23, PPSV23+PCV13, PCV15, or 
PCV20): allocated to receive V116 
Objectives Endpoints
Primary
•Objective: To evaluate the safety and 
tolerability of V116 as assessed by [CONTACT_93287] (AEs) •Solicited injection -site AEs from Day 1 
through Day 5 postvaccination
•Solicited systemic AEs from Day 1 
through Day 5 postvaccination
•Vaccine -related serious adverse events 
(SAEs) from Day 1 through the duration 
of participation in the study
•Objective: To evaluate the serotype -
specific opsonophagocytic activity (OPA) 
geometric mean titers (GMTs) at 30 days 
postvaccination for all serotyp es included 
in V116.•Serotype -specific OPA responses
08J3TW
PRODUCT: V116  13
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Objectives Endpoints
Secondary
•Objective: To evaluate the serotype -
specific Immunoglobulin G (IgG)
geometric mean concentrations ( GMCs)
at 30 days postvaccination for all 
serotypes included in V116.•Serotype -specific IgG responses
•Objective: To evaluate the serotype -
specific geometric mean fold rise 
(GMFR )and the proportion of 
participants who achieve a serotype -
specific ≥4 -fold increase from baseline to 
30 days postvaccination for both OPA 
and IgG responses for all serotypes 
included in V116.•Serotype -specific OPA and IgG 
responses
Overall Desig n:
Study Phase Phase 3
Primary Purpose Prevention
Indication Pneumococcal disease
Population Pneumococcal vaccine -experienced a dults ≥50 years of 
age
Study Type Interventional
Intervention Model Parallel
This is a multi- sitestudy.
Type of Control Cohorts 1 and 2 :Active control without placebo
Cohort 3:No treatment control
Study Blinding Cohort s1 and 2 : Double -blind with in -house blinding
Cohort 3 : Unblinded Open- label
08J3TW
PRODUCT: V116  14
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Blinding Roles Cohort s1 and 2 : 
Participants or Subjects 
Investigator
Sponsor
Cohort 3 :
No Blinding
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately 10months from the time the first 
participant (or their legally acceptable representative) 
provides documented informed consent until the last 
participant’s last study- related contact .
For purposes of analysis and reporting, the overall study 
ends when the Sponsor r eceives the last laboratory result 
or at the time of final contact [CONTACT_26355], 
whichever comes last.
Number of Participant s:
Approximately [ADDRESS_103056]: V116  15
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Intervention Groups and Du ration :
Intervention 
Group sIntervention 
Group Name [CONTACT_93340] 1: V116 V1164 µg of each 
PnPs antigen (3, 
6A, 7F, 8, 9N, 
10A, 11A, 12F, 
15A, 15C,16F, 
17F, 19A, 20, 
22F, 23A, 23B, 
24F, 31, 33F, 
35B)Single Dose IMSingle Dose at 
Visit 1 (Day 
1)Test Product
Cohort 1: 
PCV15PCV152 µg of each 
PnPs antigen (1, 
3, 4, 5, 6A, 7F, 
9V, 14, 18C, 
19A, 19F, 22F, 
23F, and 33F) 
and 4 µg of 
PnPs antigen 
6BSingle Dose IMSingle Dose at 
Visit 1(Day 
1)Comparator
Cohort 2: V116 V1164µg of each 
PnPs antigen (3, 
6A, 7F, 8, 9N, 
10A, 11A, 12F, 
15A, 15C, 16F, 
17F, 19A, 20, 
22F, 23A, 23B, 
24F, 31, 33F, 
35B)Single Dose IMSingle Dose at 
Visit 1 (Day 
1)Test Product
Cohort 2: 
PPSV23PPSV2325 µg of each 
PnPs antigen (1, 
2, 3, 4, 5, 6B, 
7F, 8, 9N, 9V, 
10A, 11A, 12F, 
14, 15B, 17F, 
18C, 19A, 19F, 
20, 22F, 23F, 
and 33F)Single Dose IMSingle Dose at 
Visit 1(Day 
1)Comparator
Cohort 3: V116 V1164 µg of each 
PnPs antigen (3, 
6A, 7F, 8, 9N, 
10A, 11A, 12F, 
15A, 15C, 16F, 
17F, 19A, 20, 
22F, 23A, 23B, 
24F, 31, 33F, 
35B)Single Dose IMSingle Dose at 
Visit 1 (Day 
1)Test Product
Admin=administration; IM=intramuscular; PCV15= pneumococcal 15 -valent conjugate vaccine 
(VAXNEUVANCE ™);PnPs=pneumococcal polysaccharide; PPSV23= pneumococcal vaccine, polyvalent (23 -
valent) ( PNEUMOVAX™23 );V116=pneumococcal 21 -valent conjugate vaccine.
Other current or former name(s) or alias(es) for study intervention(s) are as 
follows: V116 , polyvalent pneumococcal conjugate vaccine (pPCV)
08J3TW
PRODUCT: V116  16
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Total 
Number of 
Intervention 
Groups/
Arms5
Duration of 
ParticipationEach participant will participate in the study for approximately 6month s from 
the time the participant provides documented informed consent through the 
final contact.
Study Governance Committees:
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :Yes
A list of abbreviations is in Appendix 8.
08J3TW
PRODUCT: V116  17
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103057]: V116  18
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
1.3 Schedule of Activities
Study Period: Intervention and Follow -up Notes
Visit Number:[ADDRESS_103058]
Scheduled Time:Day 
[ADDRESS_103059] ion.
Assignment of Screening Number X
Inclusion/Exclusion Criteria X
Medical History X
Postrandomization Procedures
Assignment of Randomization Number X
Participant Identification Card X
Prior/Concomitant Medication and Nonstudy 
Vaccination ReviewX X X
V116 or PCV15 Administration in Cohort 1 
(Blinded)X
V116 or PPSV23 Administration in Cohort 2 
(Blinded)X
08J3TW
PRODUCT: V116  19
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Study Period: Intervention and Follow -up Notes
Visit Number:[ADDRESS_103060]
Scheduled Time:Day 
1 Day 7 Day 30 Day 90 Day 180
Visit Window -Day 7
through
Day 10 Day 30 
through
Day 44Day 76
through 
Day 104Day 166
through 
Day 194
V116 Administration in Cohort 3 ( Unblinded ) X
Provide Electronic Device or Configure 
Participant’s Own Electronic Device for eVRC
Data CollectionX
Review eVRC Data With Participant X X
Collect Electronic Device From Participant s Who 
Received an Electronic DeviceX
Complete Telephone Contact [CONTACT_93288] X X
Safety Procedures
Complete Physical Examination XPerformed by [CONTACT_93289] .
Pregnancy Test (if applicable) XFemales of reproductive potential must have a negative 
urine or serum test (consistent with local requirements 
and sensitive to ≤25 IU hCG) result before vaccination.
Body Temperature Measurement XMeasure dbefore vaccination. Participants with febrile 
illness within [ADDRESS_103061] 
30minutes postvaccination.
AE Monitoring X X X X XNonserious AEs collected through Day 30 
postvaccination; SAEs and deaths collected through 
duration of study participation.
Immunogenicity Procedures
Serum for Immunogenicity Assays X X Visit [ADDRESS_103062]: V116  20
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Study Period: Intervention and Follow -up Notes
Visit Number:[ADDRESS_103063]
Scheduled Time:Day 
1 Day 7 Day 30 Day 90 Day 180
Visit Window -Day 7
through
Day 10 Day 30 
through
Day 44Day 76
through 
Day 104Day 166
through 
Day 194
Future Biomedical Research
Blood (DNA) for FBR XFor participants who provided FBR consent.
Should be collected before vaccination at Visit 1, or at a 
later date as long as the FBR consent is obtained prior to 
collection .
Assay Development Sampl es
Serum for Optional Assay Development X XFor participants who provided consent for optional assay 
development. Visit 1 sample should be collected before 
vaccination.
AE=adverse event; DNA=deoxyribonucleic acid; eVRC=electronic v accination report card; FBR=future biomedical research; hCG=human chorionic gonadotropin; 
ID=identification; IU=international units ;PCV15= pneumococcal 15 -valent conjugate vaccine ; PPSV23= pneumococcal vaccine, polyvalent (23 -valent) ; SAE=serious adverse 
event
08J3TW
PRODUCT: V116  21
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
2 INTRODUCTION
The Sponsor is developi[INVESTIGATOR_93267] 21- valent conjugate 
vaccine (V116) for the prevention of pneumococcal disease caused by [CONTACT_93290].
2.1 Study Rationale
This Phase 3 clinical study is designed to evaluate the safety, tolerability, and 
immunogenicity of V116 in adults ≥50 years of age who previously received a pneumococcal 
vaccination ≥[ADDRESS_103064] burden in children 
<5years and adults >70 years of age [Troeger, C., et al 2018] . PCV vaccinati on has reduced 
the incidence of disease caused by [CONTACT_93291] 
(primarily children <[ADDRESS_103065] countries) and has had an indirect effect in other 
age groups. 
However, an unmet medical need exists as incr eases in IPD due to serotypes not included in 
licensed PCVs have been observed in several countries , especially in adults.
V116 is an investigational PCV designed to address this unmet medical need and includes 
Spneumoniae serotypes not included in licens ed PCVs, which account for the majority of 
IPD observed in adults .
Many countries have implemented age -based and/or risk- based recommendations for 
pneumococcal vaccination. Globally, there is variability in national pneumococcal 
vaccination recommendations and practices. Following the recent licensure in the US of 
PCV20 and PCV15, the ACIP updated recommendations in October 2021 [Kobayashi, M., et 
al 2022] . These vaccines have also recently been approved by [CONTACT_941] E MA, and updated national 
recommendations in those markets incorporating these vaccines is anticipated. This study is 
planned to enroll participants in the US, EU, and other countries; therefore, considerations 
are given to the recently updated ACIP recomme ndations, expected updates to 
recommendations globally, and the intent to remain consistent with current vaccination 
practices globally.
Adults ≥50 years of age are at elevated risk for pneumococcal disease and associated 
morbidity and mortality due to age -related physiological changes in the respi[INVESTIGATOR_2133], 
age-related immunosenescence, and an increased incidence of other medical conditions 
associated with increased risk for pneumococcal disease , independent of pneumococcal 
vaccination status [Drijkoningen, J. J 2014] [Janssens, J. P. 2004] . It is also expected that 
many of the participants in this population may have stable underlying chronic medical 
conditions that make them eligible for pneumococcal vaccination, according to prior and 
recently updated ACIP guidelines.
08J3TW
PRODUCT: V116  22
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Prior to 2021, the ACIP recommended that adults ages 19 to 64 with certain underlying 
medical conditions should receive a single dose of PPSV23 and adults ≥65 years should 
receive a single dose of PPSV23 or a single dose of PCV13 followed by a single dose of 
PPSV23 (PCV13+PPSV23) influenced by [CONTACT_93292] [Matanock, A., et 
al 2019] . Individuals who previously received a pneumococcal vaccine according to previous
ACIP recommendations (ie, PCV13 and/or PPSV23) may benefit from receiving V116 due 
to the inclusion of serotypes responsible for the majority of IPD in regions that have an 
established pediatric vaccination program.
As of 2021, ACIP guidelines recommend that adults ≥65 years of age rece ive a single dose of 
PCV20 or a single dose of PCV15 followed by a single dose of PPSV23 (PCV15+PPSV23). 
This study will also include participants who received either PCV13+PPSV23, 
PCV15+PPSV23, PPSV23+PCV13, PCV15, or PCV20 ≥1 year before enrollment, as t hese 
individuals may also benefit from vaccination with V116 [Kobayashi, M., et al 2022] .    
2.2 Background
To date, a Phase 1/2 study (V116- 001) and a Phase 1 study in Japan (V116 -002) have been 
conducted with V 116. Results from the Phase [ADDRESS_103066] the 
optimal vaccine formulation for subsequent development. Results from both studies showed 
that V116 is immunogenic and has acceptable safety and tolerability in healthy adults. Refer 
to the IB for detailed background information on V116.
2.2.1 Pharmaceutical and Therapeutic Background
Pneumococcal disease (ie, disease caused by [CONTACT_93293] ) is one of the single largest 
vaccine -preventable causes of death in children and older adults ( ≥65 years of age) 
worldwide. PCV use in children has decreased the incidence of disease caused by [CONTACT_93294]. This has resulted in decreased hospi[INVESTIGATOR_93268] ≥65 years of age, including estimated decreases of 29% and 34% in admissions due to 
IPD and noninvasive pneumococcal pneumonia, respectively [Simonsen, L., et al 2014] .In 
some countr ies, including the US, the decrease in pneumococcal disease in children 
vaccinated with PCV has led to the recommendation to vaccinate adults with PCVs. 
However, current surveillance does not definitively indicate that the use of PCVs in adults 
results in a similar reduction in pneumococcal disease [Matanock, A. 2018] . The residual 
burden of disease in the US is estimated as 24 cases of IPD per 100,000 in adults ≥65 years 
of age, and surveillance data estimates s erotypes included in currently licensed PCVs account 
for approximately 23% to 50% of these cases [Centre for Disease Control and Prevention 
2016] [Centers for Disease Control and Prevention 2019] [ Kobayashi, M. 2021] .
The residual burden of disease in adults reflects the difference in serotype distribution in 
adults compared with infants and children. An increasing incidence of disease due to 
serotypes not included in the licensed PCVs has been obs erved, particularly in adults [Miller, 
Elizabeth, et al 2011] [Moore, M. R., et al 2015] [Pi[INVESTIGATOR_63466], T. 2015] [van der Linden, M., et 
al 2015] [Golden, A. R., et al 2016] . Increases in IPD cases due to non vaccine serotypes (3, 
7F, and 19A after implementation of PCV7 ; 22F and 33F following widespread usage of 
08J3TW
PRODUCT: V116  23
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
PCV13 ) have been observed in both pediatric and older adult (≥65 years of age) populations 
in the US [Hicks, L. A., et al 2007] [Pi[INVESTIGATOR_63466], Tamara, et al 2010] [Waight, P. A., et al 2015] 
[Moore, M. R., et al 2015] [Demczuk, W. H. B., et al 2013]. Similarly, due to the limited 
serotype coverage of the currently licensed vaccines in the EU, serotype replacement due to 
nonvaccine serotypes is being observed in older adults and may decrease the potential 
additional benefit of vaccination with currently available PCVs [European Center for Disease 
Prevention and Control 2018] .
Serotypes were selected for inclusion in V116 based on available global epi[INVESTIGATOR_93269] a primary focus on data from older adults ( ≥65 years of age) in the US and EU, regions 
with an establi shed pediatric vaccination program. Based on 2018 surveillance data in US 
adults ≥65 years of age, the serotypes selected for inclusion in V116 account for 
approximately 83% of all cases of IPD, 25% to 30% of which are accounted for by [CONTACT_93295] V116 (US CDC ABC sunpublished data 2014 to 2018) [Centre for 
Disease Control and Prevention 2018] .
V116 includes serotypes not currently contained in any licensed pneumococcal vaccine. It is 
being developed to support an indication for active immunization for the prevention of 
invasive disease and pneumonia caused by S pneumoniae serotypes 3, 6A , 6C, 7F, 8, 9N, 
10A, 11A, 12F, 15A, 15B , 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in 
adults 18 years of age and older. Note that serotype 15C represents deOAc15B as the 
molecular structures for deOAc15B and 15C are similar.
2.2.2 Information on Other Study -related Therapy
[IP_ADDRESS] PCV15
Refer to approved labeling for detailed background information on PCV15.
PCV15 is a pneumococcal conjugate vaccine that includes 15 serotypes (1, 3, 4, 5, 6A, 6B, 
7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) individually conjugated to the CRM 197and 
formulated with aluminum phosphate adjuvant.
PCV15 is approved for use in the US, EU, and other countries, in adults ≥18 years of age for 
the prevention of pneumococcal disease caused by [CONTACT_93296] (indication 
may vary by [CONTACT_1606]) . 
[IP_ADDRESS] PPSV23
Refer to approved labeling for detailed background information on PPSV23.
PPSV23 is comprised of the polysaccharides from 23 of the serotypes causing disease in 
adults (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 
22F, 23F, and 33F). The formulation is not adjuvanted and no carrier protein is used.
PPSV23 was first approved in the US in [ADDRESS_103067]: V116  24
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
≥50years of age and in individuals ≥2 years of age at increased risk for pneumococcal 
disease.
[IP_ADDRESS] Pneumococcal Vaccination Guidelines
Many countries have implemented age -based and/or risk- based recommendations for 
pneumococcal vaccination. Age -based recommendations typi[INVESTIGATOR_93270] 65 years of age due 
to the increased risk of pneumococcal disease associated with age.
Prior to 2014, the US ACIP recommended that all adults ≥65 years of age receive a single 
dose of PPSV23. In 2014, ACIP recommend ed the sequential vaccination regimen of PCV13 
followed by [CONTACT_93297]23 for all adults ≥65 years of age, with the intent to reevaluate this 
recommendation. The guideline was updated in 2019 to remove the recommendation for 
routine use of PCV13 among adults ≥65 years and continued to recommend a routine single 
dose of PPSV23 for adults aged ≥65 years [Matanock, A., et al 2019]. The ACIP updated 
their guidelines in 2021 to recommend that adults ≥65 years of age should re ceive either 
PCV15 followed by [CONTACT_93297]23, or PCV20 alone [Kobayashi, M., et al 2022] . Further ,adults 
who received only PPSV23 may receive a PCV (either PCV20 or PCV15) ≥1 year after their 
PPSV23 dose [Kobayashi, M., et al 2022] . Additionally, adults who received only PCV13 are 
recommended to complete the previously recommended vaccination series with a single dose 
of PPSV23 . Currently, t here is no recommenda tion for vaccinating individuals previously 
vaccinated with PCV13 +PPSV23 , PCV15 or PCV20 .
Risk-based recommendations generally include individuals with an increased risk of 
pneumococcal disease who are categorized as immunocompetent at -risk or as high- risk. 
Conditions associated with immunocompetent at- risk include, but arenot limited to, chronic 
heart disease, chronic lung disease ( including chronic obstructive pulmonary disease, 
emphysema, and asthma ),diabetes mellitus, alcoholism, chronic liver disease (including 
cirrhosis ),and cigarette smoking . Conditions associated with high- risk include, but are not 
limited to, congenital or acquired asplenia, sickle cell disease/other hemoglobinopathies, 
chronic renal failure, congenital or acquired immunodeficiencies, generalized malignancy, 
hematologic malignancy, HIV infection, nephrotic syndrome, solid organ transplant, and 
hematopoietic stem cell transplant [Kobayashi, M., et al 2022] . In the US, recommendations 
for immunocompetent at -risk individuals 19 to 64 years of age previously included a single 
dose of PPSV23, with the exception of individuals with cochlear implants or CSF leaks ,who 
should receive PCV13 fol lowed by [CONTACT_93297]23. High -risk individuals were recommended to 
receive 1 dose of PCV13 followed by 1 dose of PPSV23 ≥8 weeks later, and an additional 
dose of PPSV23 ≥5 years later [Matanock, A., et al 2019] . Similar to the age -based 
recommendations, the ACIP guidelines were updated in 2021, and now recommend that 
immunocompetent at -risk individuals and high -risk individuals 19to 64 years of age receive 
PCV15 followed by [CONTACT_93297]23, or PCV20 alone [Kobayashi, M., et al 2022] .
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly benefit from 
treatment during participation, as clinical studies are designed to provide information abo ut 
the safety and effectiveness of an investigational medicine.
08J3TW
PRODUCT: V116  25
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103068] of currently available pneumococcal vaccines, 
pneumococcal disease in adults remains a significant unmet medical need. S pneumoniae is a 
major cause of vaccine -preventable disease worldwide, resulting in considerable morbidity 
and mortality [Troeger, C., et al 2018] . 
Vaccination with PCVs has reduced the incidence of disease caused by [CONTACT_93298] (primarily children <[ADDRESS_103069] 
countries) and has had an indirect effect in other age groups. However, in seve ral countries, 
infant vaccination with PCVs has also led to increases in IPDdue to serotypes not included 
in the licensed PCVs, particularly in adults .This has resulted in an unmet medical need in 
this population.
V116 is designed to provide significantl y broader pneumococcal disease coverage in adults 
as compared with currently licensed pneumococcal vaccines and is anticipated to have a 
generally comparable safety profile. No clinically important safety findings have been 
identified to date based on data from early phase clinical studies with V116.  
The benefit risk profile for V116 supports continued evaluation. 
In this study, a pproximately 28.6% of participants will receive either PCV15 or PPSV23, 
both of which are vaccine sindicated for the prevention of pneumococcal disease . V116 is 
expected to provide comparable immune responses to PCV15 and PPSV23 for the serotypes 
in common ,while providing additional coverage for the serotypes unique to V116. It is 
unknown if the inves tigational V116 will have the same clinical benefit as PCV15 or 
PPSV23 .
Additional details regarding specific benefits and risks for participants participating in this 
clinical study may be found in the accompanying IB and informed consent documents.
3 HYPOT HESE S, OBJECTIVES ,AND ENDPOINTS
There is no hypothesis testing in this study.
Objectives and endpoints will be evaluated in pneumococcal vaccine -experienced adults 
≥50years of age , and will be evaluated separately within each vaccination group in each of 
the following cohorts :
Cohort 1 (prior PPSV23) :randomized to receive V116 or PCV15
Cohort 2 (prior PCV13) : randomized to receive V116 orPPSV23
Cohort 3 (prior PCV13+PPSV23, PCV15+PPSV 23, PPSV23+PCV13, PCV15, or 
PCV20) :allocated to receive V116
08J3TW
PRODUCT: V116  26
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Objectives Endpoints
Primary
•Objective: To evaluate the safety and 
tolerability of V116 as assessed by [CONTACT_93287] (AEs)•Solicited injection -site AEs from Day 1 
through Day 5 postvaccination
•Solicited systemic AEs from Day 1 
through Day 5 postvaccination
•Vaccine -related serious adverse events
(SAEs) from Day 1 throug h the duration 
of participation in the study
•Objective: To evaluate the serotype -
specific opsonophagocytic activity 
(OPA) geometric mean titers (GMTs) at 
30 days postvaccination for all serotypes 
included in V116.•Serotype -specific OPA responses
Secondar y
•Objective :To evaluate the serotype -
specific Immunoglobulin G ( IgG) 
geometric mean concentrations ( GMCs)
at 30 days postvaccination for all 
serotypes included in V116.•Serotype -specific IgG responses
•Objective :To evaluate the serotype -
specific geometric mean fold rise 
(GMFR )and the proportion of 
participants who achieve a serotype -
specific ≥4 -fold increase from baseline to 
30 days postvaccination for both OPA 
and IgG responses for all serotypes 
included in V116.•Serotype -specific OPA and IgG 
responses
Tertiary/Exploratory
•Objective : To evaluate the cross -reactive 
immune responses to serotypes within a 
serogroup 30 days postvaccinatio n.•Serotype -specific OPA and IgG 
responses
08J3TW
PRODUCT: V116  27
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
4 S TUDY DESIGN
4.1 Overall Design
This Phase 3 study is being conducted to evaluate the safety , tolerability, and 
immunogenicity of V116 in participants ≥50 years of age who arepneumococcal vaccin e-
experienced. Participants are considered to be pneumococcal vaccine -experienced and 
eligible for enrollment in this study if they r eceived either PCV13, PCV15, PCV20, PPSV23, 
PCV13+PPSV23, PCV15+PPSV23, orPPSV23 +PCV 13 ≥1 year before enrollment.
Approximately 700participants will be enrolled into 1 of 3 parallel c ohorts based on the 
participant’s prior pneumococcal vaccination history:
Cohort 1: Approximately 300 participants who were vaccinated with PPSV23 ≥1 year 
prior to enrollment will be randomized in a 2:1 ratio to receive either V116 or PCV15
on Day 1 . Cohort 1 will be double -blind, parallel group, and active 
comparator -controlled. 
Cohort 2: Approximately 300 participants who were vaccinated with PCV13 ≥1 year 
prior to enrollment will be randomized in a 2:1ratioto receive either V116 or 
PPSV23 on Day [ADDRESS_103070] 50% of participants in Cohorts 1 and 2 (combined) are
≥65years of age .  
Cohort 3: Approximately 100 participants who were vaccinated with 
PCV13+PPSV23, PCV15+PPSV23, PCV15, PCV20, or PPSV23 +PCV13 ≥[ADDRESS_103071]: V116  28
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
timing and content of the safety reviews, will be outlined in the DMC charter. Information 
regarding the composition of the DMC is provided in Appendix 1 .
Blood samples for imm unogenicity assays will be drawn on Day 1 and at 30 days 
postvaccination (Visit 3) .
Specific procedures to be performed during the study, including prescribed times and 
associated visit windows, are outlined in Section 1.3 of the SoA. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
This study will evaluate the safety, tolerability, and immunogenicity of V116 in adults 
≥50years of age who were previously vaccinated with a pneumococcal vaccine . 
Thepopulation enro lled in this study is at increased risk for pneumococcal disease and its 
associated morbidity and mortality as the incidence of IPD is directly related to age, with 
over half of all cases occurring in adults ≥50 years of age [Drijkoningen, J. J 2014] .The 
vaccine -experienced population enrolled in this study may still have a risk of pneumococcal 
disease due to serotypes not included in a previously received vaccine. The study cohorts 
were selected to include comparators that are consistent with ACIP guidelines and
anticipated updates to global vaccination guidelines. The randomization ratio of 2:[ADDRESS_103072] an increased risk of 
pneumoc occal disease due to chronic comorbid condition. Among adults, persons with 
chronic illnesses ( eg,chronic heart disease, chronic lung disease, diabetes) have a 3 -to 6-fold 
increased risk of IPDcompared with healthy adults, and rates increase with the number of 
underlying conditions present [Kyaw, M. H., et al 2005] . Adults with stable chronic medical 
conditions will be included in this study. These individuals are generally categorized as being 
immunocompetent at -risk, reflecting the understanding that while they are at an increased 
risk of pneumococcal disease, their immune responses are not impacted by [CONTACT_93299] [Curcio, D., et al 2015] [Weycker, D., et al 2010] [van Hoek, A. J., et al 
2012] .
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Immunogenicity Endpoints
The immunogenicity endpoints are consistent with previous studies evaluating PCVs.
Sera from participants will be used to assess vaccine -induced, anti -PnPs serotype -specific 
OPA and IgG responses using thevalidated MOPA and Pn ECL assays, respectively.
Immunogenicity endpoints will be evaluated for all serotypes included in V116 and for 
cross -reactive serotypes within a serogroup.
08J3TW
PRODUCT: V116  29
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103073] en and adults [Centers for Disease Control and 
Prevention 2010] [Anttila, M., et al 1999] [Romero -Steiner, S., et al 1997] . OPA assesses 
levels of functional antibodies capable of opsonizing pneumo coccal capsular polysaccharides 
for presentation to phagocytic cells for engulfment and subsequent killing, and therefore is 
considered an important immunologic surrogate for protection against IPD in adults. It is 
noted that IgG antibody concentration and OPA titer threshold values that correlate with 
protection in adults have not been defined; however, the OPA responses areconsidered 
accepted endpoint sfor the evaluation of novel pneumococcal vaccines in adults.
The OPA GMT, IgG GMC, GMFR , and proportion of participants with 4 -fold rise in OPA 
and IgG responses are acceptable assessments used to evaluate novel PCVs.
Details on the immunogenicity endpoints evaluated in this study can be found in 
Section 9.4.1.
[IP_ADDRESS] Safety Endpoints
Safety information will be collected from all participants on an eVRC. The eVRC used to 
record AEs during the postvaccination periods (Section 8.1.9) is structured as recommended 
in the final US FDA Patient- reported Outcome Guidance [U.S. Food and Drug 
Administration 2009] .
The safety endpoints (ie, AEs and temperature) evaluated in this study are consistent with 
previous studies of V116 and published data from marketed PCVs. Detailed information for 
the safety endpoints evaluated in this study can be found in Section 9.4.2.
Definitions and reporting requirements for AEs are provided in Appendix 3.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct FBR on specimens for which consent was provided during this 
study. This research may include genetic analyses (DNA), gene expression profiling (RNA), 
proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, 
depending on whi ch specimens are consented for FBR .
Such research is for biomarker testing to address emer gent questions not described elsewhere 
in the protocol and will only be conducted on specimens from appropriately consented 
participants. The objective of coll ecting/retaining specimens for FBR is to explore and 
identify biomarkers that inform the scientif ic understanding of diseases and/or their 
therapeutic treatments. The overarching goal is to use such information to develop safer, 
more effective drugs/vaccines, and/or to ensure that participants receive the correct dose of 
the correct drug/vaccine at th e cor rect time. The details of FBR r esearch are presented in
Appendix 6.
08J3TW
PRODUCT: V116  30
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
4.2.2 Rationale for the Use of Comparator /Placebo
Placebo -controlled clinical studies for new PCVs are no longer practical given the proven 
clinical efficacy and widespread use of licensed pneumococcal vaccines worldwide.
The study cohorts are determined by a participant’s prior pneumococcal vaccination history. 
The comparator of PCV15 and PPSV23 in Cohort 1 and Cohort 2, respectively, reflects the 
recently updated ACIP guidelines for individuals who previously received a pneumococcal 
vaccination [Kobayashi, M., et al 2022] (see Section [IP_ADDRESS] ).
The sequential regimen of a PCV followed by [CONTACT_93297]23 is recommended in many countries 
for individuals at increased risk for pneumococcal disease [Nuorti, J. P. and Whitney, C. G. 
2010] [Robert Koch Institut 2017] .With the additional serotypes included in V116, there 
may be additional benefit in vaccinating individuals who have previously received 
PCV13+PPSV23, PCV15+PPSV23, PPSV23+PCV13, PCV15, or PCV20. As data on the 
public health benefit of additional vaccination for these individuals at this time is limited, 
there is no comparator in open -label Cohort 3.
4.3 Justification for Dose
The V116 dose of 4 µg/each PnPs was selected based on review of safety and 
immunogenicity data from the Phase 1 and Phase 2 studies. In Phase 1, 2doses of V116 were 
evaluated: a single dose containing 2 µg/each PnPs and a single dose of 4 µg/each PnPs. 
Based on the data from Phase 1, the V116 dose of 4 µg/each PnPs was selected for further 
evaluation i n Phase 2. Results from Phase 2 showed that the V116 dose of 4 µg/each PnPs is 
well tolerated and generate sserotype -specific immune response s.These data support the 
selection of the V116 dose of 4 µg/each PnPs for further development in Phase [ADDRESS_103074] label ingof 
VAXNEUVANCE™ and PNEUMOVAX™[ADDRESS_103075] participant (or their legally acceptable representative) 
provides documented informed consent . The overall study ends when the last participant 
completes the last study -related contact , withdraws consent , or is lost to follow -up (ie, the 
participant is unable to be contact[CONTACT_19379]) .
For purposes of analysis and reporting, the overall study ends when the Sponsor receives the 
last laboratory result or at the time of final contact [CONTACT_26355], whichever comes 
last.
If the study includes countries in the European Economic Area (EEA), the local start of the 
study in th e EEA is defined as First Site Ready (FSR) in any Member State .
08J3TW
PRODUCT: V116  31
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
4.4.1 Clinical Criteria f orEarly Study Termination
The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the risk/ benefit ratio to the study population 
as a whole is unacceptable. In addition, further recruitment in the study or at (a)particular 
study site(s) may be stopped due to insufficient compliance with the protocol, GCP, and/or 
other applicable regulatory requ irements, procedure -related problems or the number of 
discontinuations for administrative reasons is too high .
[ADDRESS_103076] for Clinical Trials (Appendix 1), this study includes 
participants of varying age (as applicabl e), race, ethnicity, and sex (as applicable). The 
collection and use of these demographic data will follow all local laws and participant 
confidentiality guidelines while supporting the study of the disease, its related factors, and 
the IMP under investiga tion.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study if the participant meets all of the 
following criteria :
Type of Participant and Disease Characteristics
1.The participant may have underlying chronic condition sif they are assessed to be stable 
as per the investigator’s judgment.
2.Ispneumococcal vaccine -experience d, defined as priorreceipt (≥1year before 
enrollment) of PCV13, PCV15, PCV20, PPSV23 ,PCV13+PPSV23, PP SV23+PCV13, or 
PCV15+ PPSV23 .
Demographics
3.Ismale or female , ≥50years of age ,at the time of informed consent.
08J3TW
PRODUCT: V116  32
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103077] one of the following conditions applies: 
•Not a WOCBP
OR
•A WOCBP and:
-Uses an acceptable contraceptive method, or be abstinent from heterosexual 
intercour se as their preferred and usual lifestyle (abstinent on a long -term and 
persistent basis), as described in Appendix [ADDRESS_103078] dose of study intervention. The investigator should 
evaluate the po tential for contraceptive method failure (ie, noncompliance, recently 
initiated) in relationship to the first dose of study intervention. Contraceptive use by 
[CONTACT_93300] e participating in clinical studies
-Has a negative highly sensitive pregnancy test (urine or serum as required by [CONTACT_13125]) within [ADDRESS_103079] 
cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is 
required. In such cases, the participant must be excluded from participation if the 
serum pregnancy result is positive. Additional requirements for pregnancy testing 
during and after study intervention are in Section 8.3. 2.
-Medical history, menstrual history, and recent sexual activity has been reviewed by 
[CONTACT_93301] a woman with an early undetected 
pregnancy.
Informed Consent
5.The participant (or legally acceptable representative) has provide ddocumented informed 
consent for the study. The participant may also provide documented informed consent for 
FBR and/or assay development sample collection. However, the partic ipant may be 
enrolled in the study without providing consent for FBR or assay development sample 
collection.
Additional Categories
6.The participant has the ability to complete eVRC data collection without assistance based 
on judgment of the investigator .
08J3TW
PRODUCT: V116  33
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103080] be excluded from the study if the participant meets any of the following 
criteria :
Medical Conditions
1.Has a history of IPD (positive blood culture, positive cerebrospi[INVESTIGATOR_63469], or 
positive culture at another sterile site) or known history of other culture -positive 
pneumococcal disease within 3 years of Visit 1 (Day 1).
2.Has a known hypersensitivity to any component of V116 ,PCV15, PCV20, or PPSV23,
including diphtheria toxoid .
3.Has a known or suspected impairment of immunological function including, but not 
limited to, a history of congenital or acquired immunodeficiency, documented HIV 
infection, functional or anatomic asplenia, or history of autoimmune disease (including 
but not limited to the autoimmune conditions outlined in the Investigator Trial File 
Binder for this study).
4.Has a coagulation disorder contraindicating intramuscular vaccination.
5.*Had a recent febrile illness (defined as oral or tympanic temperature ≥100.4°F 
[≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic 
therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
6. Has a known malignancy that is progressing or has required active treatment within the 
3years p rior to signing the informed consent. Note : Participants with basal cell and/or
squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical 
cancer in situ) that have undergone potentially curative therapy are not excluded.
Prior/Concomitant Therapy
7.Received PPSV23 followed by [CONTACT_93302]15 or PCV20 .
8.*Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for 
≥14consecutive days and has not completed intervention ≥14 days before receipt of
study vaccine .Note : physiologic replacement doses (prednisone equivalent of 
approximately 5 mg/day), t opi[INVESTIGATOR_2855], ophthalmic, intra -articular or soft -tissue (eg, bursa, 
tendon steroid injections ), and inhaled/nebulized steroids are permitted.
9.Is currently receiving immunosu ppressive therapy, including chemotherapeutic agents or 
other immunotherapi[INVESTIGATOR_014]/immunomodulators used to treat cancer or other conditions, and 
interventions associated with organ or bone marrow transplantation, or autoimmune 
disease.
10.*Received any nonlive va ccine ≤14 days before receipt of study vaccine or is scheduled 
to receive any nonlive vaccine ≤30 days after receipt of any study vaccine. Exception : 
08J3TW
PRODUCT: V116  34
PROTOCOL/AMENDMENT NO.: 006-[ADDRESS_103081] be given ≥7 days before or ≥15 days after receipt of study 
vaccine .
11.*Received any live virus vaccine ≤30 days before receipt of study vaccine or is scheduled 
to receive any live virus vaccine ≤30 days after receipt of study vaccine .
12.Received a blood transf usion or blood products, including immunoglobulin ≤[ADDRESS_103082] until the Day 
30 postvaccination blood draw is complete. Autologous blood 
transfusions are not consi dered an exclusion criterion .
Prior/Concurrent Clinical Study Experience
13.Is currently participating in or has participated in an interventional clinical study with an 
investigational compound or device within 2 months of participating in this current study .
Diagnostic Assessments
Not A pplicable
Other Exclusions
14.In the opi[INVESTIGATOR_871], has a history of clinically relevant drug or alcohol use 
that would interfere with participation in protocol -specified activities.
15.Has history or current evidence of any condition, therapy, laboratory abnormality, or 
other circumstance that might expose the participant to risk by [CONTACT_6231], 
confound the results of the study, or interfere with the participant’s participation for the 
full dur ation of the study.
16.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
For items with an asterisk (*), if the participant meets these e xclusion criteria, Visit 1 
may be rescheduled for a time when these criteria are not met.
Country -specific criteria are included in Appendix 7.
5.3 Lifestyle Considerations
No lifestyle restrictions are required .
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently allocated/ randomized in the study . A minimal set of screen -failure 
information is required to ensure transparent reporting of screen- failure participants to meet
08J3TW
PRODUCT: V116  35
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
the CONSORT publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen- failure details, eligibility 
criteria, and any AEs or SAEs meeting reporting requirements as outlined in the data entry 
guidelines.
5.5 Participant Replacement Strategy
A participant who withdraws from the study will not be replaced.
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protoco l.
Clinical supplie s (V116 , PCV15, PPSV23 )will be packaged to support enrollment . Clinical 
supplies will be affixed with a clinical label in accordance with regulatory requirement s.
6.1 Study Intervention(s) Administered
The study interventions to be used in this study areoutlined inTable [ADDRESS_103083]: V116  36
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Table 1 Study Intervention s
Arm 
Name [CONTACT_93341](s)Dosage 
Level(s)Route of 
Admin.Vaccination 
Regimen UseIMP or 
NIMP /
AxMP Sourcing
Cohort 1: 
V116Experimental Pneumococcal 
21-valent 
conjugate 
vaccineBiological/
VaccineSterile 
Solution 
(Prefilled 
Syringe)4 µg of each PnPs 
antigen (3, 6A, 7F, 8, 
9N, 10A, 11A, 12F, 
15A, 15C, 16F, 17F, 
19A, 20, 22F, 23A, 
23B, 24F, 31, 33F, 
and 35B)0.5 mL IM Single D ose 
at Visit 1
(Day 1)Test 
ProductIMP Central
Cohort 1:
PCV15Active 
ComparatorPneumococcal 
15-valent 
conjugate 
vaccineBiological/
VaccineSterile 
Suspension 
(Prefilled 
Syringe)2 µg of each PnPs 
antigen (1, 3, 4, 5, 
6A, 7F, 9V, 14, 18C, 
19A, 19F, 22F, 23F, 
and 33F) and 4 µg of 
PnPs antigen 6B0.5 mL IM Single D ose 
at Visit 1
(Day 1)Comparator IMP Central
or local
Cohort 2: 
V116Experimental Pneumococcal 
21-valent 
conjugate 
vaccineBiological/
VaccineSterile 
Solution 
(Prefilled 
Syringe)4 µg of each PnPs 
antigen (3, 6A, 7F, 8, 
9N, 10A, 11A, 12F, 
15A, 15C, 16F, 17F, 
19A, 20, 22F, 23A, 
23B, 24F, 31, 33F, 
and 35B)0.5 mL IM Single D ose 
at Visit 1 
(Day 1)Test 
ProductIMP Central
Cohort 2: 
PPSV23Active 
ComparatorPneumococcal 
Vaccine, 
Polyvalent (23 -
valent)Biological/
VaccineSterile 
Solution 
(Prefilled 
Syringe)25 ug of each PnPs 
antigen (1, 2, 3, 4, 5, 
6B, 7F, 8, 9N, 9V, 
10A, 11A, 12F, 14, 
15B, 17F, 18C, 19A, 
19F, 20, 22F, 23F, 
and 33F )0.5 mL IM Single D ose 
at Visit 1 
(Day 1)Comparator IMP Central 
or local
08J3TW
PRODUCT: V116  37
PROTOCOL/AMENDMENT NO.: 006-02
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Arm 
Name [CONTACT_93341](s)Dosage 
Level(s)Route of 
Admin.Vaccination 
Regimen UseIMP or 
NIMP /
AxMP Sourcing
Cohort 3: 
V116 Experimental Pneumococcal 
21-valent 
conjugate 
vaccineBiological/
VaccineSterile 
Solution 
(Prefilled 
Syringe)4 µg of each PnPs 
antigen (3, 6A, 7F, 8, 
9N, 10A, 11A, 12F, 
15A, 15C, 16F, 17F, 
19A, 20, 22F, 23A, 
23B, 24F, 31, 33F, 
and 35B)0.5 mL IM Single D ose 
at Visit 1 
(Day 1)Test 
ProductIMP Central
Admin =administration; IM=intramuscular; IMP=investigational medicinal product; NIMP/AxMP =non -investigational /auxiliary medicinal product ; PCV15= pneumococcal 15 -
valent conjugate vaccine ( VAXNEUVANCE™ ); PnPs=pneumococcal polysaccharide; PPSV23= pneumococcal vaccine, polyvalent (23- valent) ( PNEUMOVAX™23 ); 
V116=pneumococcal 21 -valent conjugate vaccine .
The classification of IMP and N IMP/AxMP in this table is based on guidance issued by [CONTACT_93303] n Economic Area .
Country differences with respect to the definition /classification of IMP and NIMP /AxMP may exist. In these circumstances, local legislation is followed.
08J3TW
PRODUCT:   V116  38
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
All supplies indicated in Table 1 will be provided per the “Sourcing” column depending on 
local country operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/batch number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc .).
Refer to Section 8.1.[ADDRESS_103084](s), which is legally marketed, provided for use in this 
study are: VAXNEUVAN CE™ prefilled syringes and PNEUMOVAX™23 prefilled 
syringes . Refer to Section 8.4.8 and Appendix 4 for reporting events associated with these 
devices.
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_103085] be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, rec onciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
08J3TW
PRODUCT:   V116  39
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103086]/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropr iate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assign ment
Intervention allocation/r andomization will occur centrally using an IRT system. There are 5
study intervention arms. Participants will be assigned randomly in a 2:1ratio to receive either 
V116 orPCV15 (Cohort 1), or V116 or PPSV23 (Cohort 2) . All participants in the open -
label Cohort 3 will receive V116 .
6.3.2 Stratification
Intervention randomization in Cohorts 1 and 2 will be stratified according to the following 
factors:
1.Participant age at time of randomization (50 to 64 vs≥65 years of age )
2.Time since last pneumococcal vaccination (1to 4vs 5to 9vs ≥10years )
No stratification based on age, sex, or other characteristics will be used in Cohort 3.
6.3.3 Blinding
Cohorts 1 and 2
Adouble -blinding technique with in- house blinding will be used. V116, PCV15, and 
PPSV23 will be prepared and/or dispensed in a blinded fashion by [CONTACT_93304] . The participant, the investigator, and Sponsor personnel or 
delegate(s) who are involved in the clinical evaluation of the participants are unaware of the 
intervention assignments .
Because V116, PCV15, and PPSV23 have different appearances, anunblinded pharmacist 
(or qualified study -site personnel) will be responsible for receiving, maintaining, preparing 
and/or dispensing, and administering these study vaccines (Section 8.1.8).
08J3TW
PRODUCT:   V116  40
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103087] between the unblinded study site perso nnel and study participants 
is strictly prohibited for any study- related procedures/assessments other than the 
administration of study vaccines. Blinded site personnel will be responsible for all other 
study procedures/assessments specified in Section 1.3.
An unblinded Clinical Research Associate will monitor vaccine accountability at the study 
site. All other Sponsor personnel or delegate(s) directly involved with the conduct of this 
study will remain blinded to the participant- level intervent ion assignment in Cohorts 1 and 2.
See Section 8.1.12 for a description of the method of unblinding a participant during the 
study should such action be warranted.
Cohort 3
Cohort 3 is open- label ; therefore, the Sponsor, investigator, and participant will know the 
vaccine administered .Although V116 is provided open -label to participants in Cohort 3, it 
will also be prepared and/or dispensed and administered by [CONTACT_93305] (or 
qualified study -site personnel) for consistency. Procedures for handling, preparing, and 
administering the unblinded vaccines are located in the Investigator Trial File Binder.
6.4 Study Intervention Compliance
Given that a single dose of V116 , PPSV23 or PCV15 will be administered in this study, 
intervention compliance will no t be assessed.
6.5 Concomitant Therapy
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed
during the ongoing study (Section 5.2) .The investigator should discuss any questions 
regarding this with the Sponsor Clinical Director . The final decision on any supportive 
therapy or vaccination rests with the investigator and/or the participant ’s primary physician. 
It is important to record the use of any analgesic or antipyretic medication that occurs on the 
day of vaccination on the eVRC and appropriate eCRF.
Listed below are specific restrictions for concomitant therapy or vaccination:
•Administration of a nonstudy pneumococcal vaccine is prohibited during the study.
•Nonstudy vaccines may only be administered before or after the receipt of study vaccines 
according to the time frames specified in the Exclusion Criteria (Section 5.2).
•Receipt of systemic corticosteroids ( prednisone equivalent ≥20 mg/day ) for ≥14 
consecutive days is prohibited from 14 days before vaccination through 30 days 
following vaccination .Note : physiologic replacement doses (prednisone equivalent of 
approximately 5 mg/day), topi[INVESTIGATOR_2855] , ophthalmic, intra articular or soft -tissue (eg, bursa, 
tendon steroid injections), and inhaled/nebulized steroids are permitted.
08J3TW
PRODUCT:   V116  41
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant ma nagement. 
Use of prior and concomitant medications/vaccinations should be recorded as described in 
Section 8.1.5.
Country -specific requirements for concomitant therapy are included in Appendix 7.
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study.
6.6 Dose Modification
No dose modification is allowed in this study.
6.7 Intervention After the End of the Study
There is no study -specified intervention after the end of the study.
6.8 Clinical Supplies Disclosure
This study is blinded but supplies are provided as open label ; therefore, an unblinded 
pharmacist or qualified study- site personnel will be used to blind supplies. Study intervention
identity (name, strength, or potency) is inc luded in the label text; random code/disclosure 
envelopes or lists are not provided.
The emergency unblinding call center will use the intervention/randomization schedule for 
the study to unblind participants and to unmask study intervention identity. The emergency 
unblinding call center should only be used in cases of emergency (see Section 8.1.12). Ifthe 
emergency unblinding call center is not available for a given site in this study, the central 
electronic intervention randomization system (IRT) sho uld be used to unblind participants 
and to unmask study intervention identity. The Sponsor will not provide random 
code/disclosure envelopes or lists with the clinical supplies.
See Section 8.1.[ADDRESS_103088]:   V116  42
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103089] be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled prot ocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific det ails regarding withdrawal from FBR ,are outlined in Section 
8.1.11. The procedures to be performed should a participant repeatedly fail to return for 
scheduled visits and/or if the study site is unable to contact [CONTACT_88683] 7.3.
7.[ADDRESS_103090] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importanc e of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing a ddress or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and analysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
•Study procedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
08J3TW
PRODUCT:   V116  43
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegatio n of 
study- site personnel responsibilities will be docu mented in the Investigator Trial File 
Binder (or equivalent).
•All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, a s applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be u sed for screening or baseline purposes 
provided the procedure met the protocol -specified criteria and w ere performed within the 
time frame defined in the SoA.
•Additional evaluations/testing may be deemed necessary by [CONTACT_88686]. In some cases, such evaluation/testing 
may be potentially sensi tive in nature (eg, HIV, hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those regulations.
The maximum am ount of blood collected from each participant at each visit will not exceed 
80mL, and the total amount of blood collected over the duration of the study will not exceed 
150mL(Table 2 ).
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
Table 2 Approximate Blood Volumes Drawn by [CONTACT_93306] 1 Visit 3 Total
Parameter Approximate Blood Volume
Immunogenicity assessment 30mL 30mL 60mL
DNA for Future Biomedical Researcha8.5mL N/A 8.5 mL
Assay developmenta40 mL 40 mL 80 mL
Expected total 78.5 mL 70mL 148.5 mL
DNA= deoxyribonucleic acid; N/A=not applicable
aSamples for future biomedical research and assay development will only be obtained from participants who provide 
separate consent for collection of these optional samples .
08J3TW
PRODUCT:   V116  44
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant (or their legally 
acceptable representative ) prior to participating in thisclinical study or FBR . If there are 
changes to the participant’s status during the study (eg, health or age of majority 
requirements), the investigator or medically qualified designee must ensure the appropriate 
documented informed consent is in place.
[IP_ADDRESS] General Informed Consent
Informed c onsent given by [CONTACT_19429] a consent form . The form must include the study protocol number, study 
protocol title, dated signature , and agreement of the participant ( orhis/her l egally acceptable 
representative ) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB/IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant’s willingness to 
continue participation in the study. The communication of this information will be provided 
and documented vi a a revised consent form or addendum to the original consent form that 
captures the participant’s or the participant’s legally acceptable representative’s dated 
signature.
Specifics about the study and the study population are to be included in thestudy i nformed
consent form.
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically quali fied designee will explain the FBR consent to the 
participant, or the participant’s legally acceptable representative, answer all of his/her 
questions, and obtain documented informed consent before performing any procedure related 
to FBR . A copy of the informed consent will be given to the participant before performing 
any procedure related to FBR .
[IP_ADDRESS] Consent and Collection of Specimens for Optional Assay Development
The investigator or medically qualified designee will explain the consent for the optional 
assay development bloo d samples to the participant, answer all of their questions, and obtain 
08J3TW
PRODUCT:   V116  45
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
documented informed consent before performing any procedure -related to the optional assay 
development blood samples collection. A copy of the informed consent will be given to the 
participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the participant qualifies for the study.
8.1.[ADDRESS_103091] information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides documented informed consent. At the time of intervention
randomization, site personnel will add the treatment /randomization number to the participant 
identification card.
The participant IDcard also contains contact [CONTACT_93307] a health care provider can obtain information about study intervention in 
emergency situations where the invest igator is not available.
8.1.4 Medical History
A medical history will be obtained by [CONTACT_27404]. The participant’s 
relevant medical history for the 5 years before Visit 1will be obtained to ensure that the 
participant satisfies the i nclusion and exclusion criteria of the study. History of tobacco use 
will be collected for all participants.
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee must review and record the following in the 
participant’s source documents and on the appropriate eCRF before vaccination at Visit 1:
•Prior vaccinations and medication taken by [CONTACT_78772] 30 days before study 
vaccination at Visit 1.
•History of prior pneumococcal vacci nation regardless of timing prior to Visit 1.
•Any analgesic or antipyretic medication taken on the day of vaccination before 
vaccination.
08J3TW
PRODUCT:   V116  46
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record vaccinations and medications, if any, taken 
by [CONTACT_93308].
Any analgesic or antipyretic medication taken must be recorded on the eVRC and 
appropriate eCRF.
The participant will use their eVRC (Section 8.1.9) to record new and/or concomitant 
medications taken and nonstudy vaccines received from the day of each vaccination through 
[ADDRESS_103092] not be reused for 
different participants.
8.1.7 Assignment of Treatment/ Randomization Numb er
All eligible partici pants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment randomization. Once a 
treatment /randomization number is assigned to a participant, it can never b e reassigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
Unblinded study personnel will prepare and administer all study vaccines (Section 6.3.3).
The unblinded study personnel who administer study vaccines should not have contact [CONTACT_93309] -related procedures/assessments for any cohort .
Blinded site personnel will not be present in the examination room when study vaccines are 
administered for Cohorts 1 and 2.
Study vaccines should be prepared and administered by [CONTACT_93310] (eg, physician, nurse, physician’s assistant, nurse practitioner, 
pharmacist, or medical assistant) as allowed by [CONTACT_5737]/state, country, and institutional 
guidance. Procedures for handling, preparing, and administering the unblinded vaccines are 
provided in the Investigator Trial File Binder.
Study vaccine will be administered as a single IM injection, preferably in the deltoid region 
of the participant’s arm, according to the schedule specified in Section 1.3. Adequate 
treatment provision, including epi[INVESTIGATOR_93271] ,should 
08J3TW
PRODUCT:   V116  47
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
be available for immediate use should an anaphylactic or anaphylac toid reaction occur 
[Centers for Disease Control and Prevention 2015] .
[IP_ADDRESS] Timing of Dose Administration
Study vaccines will be administered as indicated in Section 1.3. Vaccinations may be 
administered at any time of day and without regard to timing of meals.
All participants will be observed for at least 30 minutes after vaccination for any immediate 
reactions (Section 8.3.4). This observation must be performed by [CONTACT_77128] 
(Section 6.3.3).
Partic ipants must not have a fever reported within 72 hours before vaccination (Section 1.3 
and Section 8.3.3).
Administration of pregnancy tests (if applicable) must be performed before vaccine 
administration.
The collection of blood samples should be performed before vaccine administration.
8.1.[ADDRESS_103093]
TheVRC is structured as recommended in the final Food and Drug Administration Patient -
reported Outcome Guidance [U.S. Food and Drug Administration 2009] . 
The participant will use the eVRC to record body temperature (Section 8.3.3), solicited 
injection- site AEs, and solicited systemic AEs (Section [IP_ADDRESS]). Unsolicited AEs (Section 
[IP_ADDRESS]), concomitant medications (including use of any analgesic or antipyretic medication), 
and nonstudy vaccinations (Section [IP_ADDRESS]) will also be reported. Participants will be 
provided an electronic device or have their own electronic device configured, if compatible, 
to complete the eVRC.
The investigator or delegate will review the data captured on the eVRC with the participant 
as indicated in Section 1.3. Any differences between eVRC data and AEs entered into the 
clinical database must be clearly explained in the participant’s source documentation.
8.1.[ADDRESS_103094] the participant (or the participant’s legally acceptable 
representative, as applicable) as indicated in Section 1.[ADDRESS_103095] Questionnaire provided by [CONTACT_1034]. Data to be reported 
from this discussion will include SAEs and/or any updates to previously reported safety 
information.
8.1.11 Discontinuation and Withdrawal
Participants who rece ive a single -dose intervention cannot discontinue study intervention
(see Section 7.1) .
08J3TW
PRODUCT:   V116  48
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Participants who withdraw from the study should be encouraged to complete all applicable 
activities scheduled for the final study visit at the time of withdrawal. Any AEs that are 
present at the time of withdrawal should be followed in accordance with the safety 
requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for FBR . Participants may withdraw consent at any 
time by [CONTACT_88690]. If medical records for the study are still available, 
the investigator will contact [CONTACT_75355] 
(clinical.specimen.management@ MSD .com). Subsequen tly,the participant’s consent for 
FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming 
the withdrawal. It is the responsibility of the investigator to inform the participant of 
completion of withdrawal. Any analyses in progress at the time of request for withdrawal or 
already performed before the request being received by [CONTACT_88691]. No new analyses would be generated 
after the request i s received.
If the medical records for the study are no longer available (eg, if the investigator is no longer 
required by [CONTACT_88692]) or the specimens have been 
completely anonymized, there will no longer be a link between the participant’s personal 
information and their specimens. In this situation, the request for specimen withdrawal 
cannot be processed .
8.1.12 Participant Blinding/Unblindi ng
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSAR Y FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the investigator or medically qualified designee (consistent 
with local requirements) needs to identify the intervention used by a participant and/orthe 
dosage administered , he/she will contact [CONTACT_88693] a request for emergency unblinding. As requested by [CONTACT_19445], the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor. Before contact[CONTACT_88694] a participant’s intervention assignment, the 
investigator who is a qualified physician should m ake reasonable attempts to enter the
intensity grade of the AEs observed, the relation to study intervention, the reason thereof , etc, 
in the medical record. If it is not possible to record this assessment in the medical record 
before the unblinding, the unblinding should not be delayed.
If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and 
person performing the unblinding) must be documented promptly, and the Sponsor Clinical 
Director notified as soon a s possible.
08J3TW
PRODUCT:   V116  49
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103096], the investigator, site personnel, and Sponsor 
personnel may be unblinded so that the appropriate follow -up medical care can be provided 
to the participant.
Participants whose trea tment assignment has been unblinded by [CONTACT_93311]/or nonstudy treating physician must be discontinued from study 
intervention, but should continue to be monitored in the study.
Additionally, the investigator or medically qualified d esignee must go into the IRT system 
and perform the unblind in the IRT system to update drug disposition. I fthe emergency 
unblinding call center is not available for a given site in this study, the IRT system should be 
used for emergency unblinding i fthis is required for participant safety.
8.1.13 Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documenta tion at the 
study sit e.
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure vaccine -induced OPA and IgG responses. 
These endpoints will be tested for all immunogenicity blood draws specified in Section 1.3. 
Blood collection, storage, and shipment instructions for serum samples will be provided in 
the operations/laboratory manual.
The MOPA will be used for measuring OPA responses. Opsonization of pneumococci for 
phagocytosis is an important mechanism by [CONTACT_93312]. The OPA assay is a useful tool for assessing the protective function 
of serotype- specific antibodies and, therefore, the immunogenicity of pneumococcal vaccine 
formulations.
Serotype -specific IgG will be measured using the Pn ECL assay to assess the concentration 
of binding antibodies to capsular polysaccharide of S pneumoniae .
After completion of immunogenicity testing to evaluate the study objectives, serum samples 
will be stored to conduct any additional study- related testing as requested by [CONTACT_63503] . For participants who provide optional consent for FBR , leftover sera 
from the study may be used for other purposes, such as the development and/or val idation of 
pneumococcal assays after completion of all study- related immunogenicity testing.
8.2.[ADDRESS_103097]:   V116  50
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
[Burton, Robert L. and Nahm, Moon H. 2006] . The ability of the assay to simultaneously test 
[ADDRESS_103098] dilution that gives ≥50% 
bacterial killing, as determined by [CONTACT_93313]. The Sponsor 
has developed and optimized the MOPA in a high -throughput mi crocolony platform, which 
not only covers all 21 serotypes in V116, but also includes serotypes 6C and 15B so that 
antibodies induced by [CONTACT_93314] 6A and 15C but cross -reactive to serotypes 6C and 
15B, respectively, can be measured. The assay has been validated for various performance 
parameters of the assay including precision, ruggedness, relative accuracy/dilutional 
linearity, and the limit of detection of the assay. 
8.2.2 Pneumococcal Electrochemiluminescence Assay
The Sponsor has developed, optimize d, and validated a multiplex, ECL -based detection 
method for the quantitation of IgG serotype -specific antibodies. This multiplexed ECL assay 
not only detects all 21 serotypes contained in V116 but also detects serotypes 6C and 15B so 
that antibodies induc ed by [CONTACT_93314] 6A and 15C but cross -reactive to serotypes 6C 
and 15B, respectively, can be measured. The ECL assay is based on the Meso -Scale 
Discovery technology, which employs disposable multispot microtiter plates. Briefly, PnPs 
are bound to th e surface of 96- well 10 plex carbon microplates, and serum containing 
purported anti- PnPs antibodies is added. The anti -PnPs antibodies bind to the coated plates 
and form an antibody -antigen complex. The bound antibody -antigen complex can be detected 
using a ruthenium labeled anti -human IgG. Plates are read by [CONTACT_93315].
 Assay validation studies showed excellent 
performance operating characteristics for precision (intra -and inter -assay), dilutability, 
ruggedness (to different plate lots and analysts), relative accuracy, and specificity. 
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided. 
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination will be conducted by [CONTACT_88696] (consistent with local requirements) per institutional standard before vaccination at 
Visit 1.
Findings related to the physical examinations should be documented in the source 
documents. Investigators should pay special attention to clinical signs related to previous 
serious illnesses .
CCI
CCI
CCI
08J3TW
PRODUCT:   V116  51
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103099] consistent with loca l requirements (sensitive to at least 25 IU hCG) must be 
performed before vaccination at Visit [ADDRESS_103100] be negative before vaccination can occur. 
A detailed definition of WOCBP is provided in Appendix 5.
•Pregnancy testing:
-Pregnancy testing requirements for study inclusion are described in Section 5.1.
-Additional serum or urine pregnancy tests may be performed, as determined 
necessary by [CONTACT_31837], to establish the absence 
of pregnancy at any time during the subject's participation in the study.
8.3.3 Body Temperature Measurement
Each participant’s body temperature must be taken by [CONTACT_3449] -site staff before vaccination as 
described in Secti on 1.3. Participants who have febrile illness (defined as oral or tympanic 
temperature ≥100.4°F [≥38.0°C]; axillary or temporal temperature ≥99.4°F [≥37.4°C]) 
<72hours before vaccination must be rescheduled.
Participants will also record oral body tempera ture measurements using the eVRC 
(Section 8.1.9) from Day [ADDRESS_103101] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory re port, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those wh ich are not associated with the underlying disease, unless 
judged by [CONTACT_19448]’s condition.
All protocol -required laboratory assessments, as defined in Appendix 2, must be 
conducted in accordance w ith the laboratory manual and the SoA.
08J3TW
PRODUCT:   V116  52
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
For any laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_103102] dose of study intervention, 
every attempt should be made to perform repeat assessments until the values return to 
normal or baseline or if a new baseline is established as determined by [CONTACT_093].
8.4 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event re ports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators need to document if an SAE was associated with a medication er ror, misuse, or 
abuse . Investigators remain responsible for following up AE s, SAEs, and other reportable 
safety events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
anAE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality .
8.4.[ADDRESS_103103] be reported by [CONTACT_93316], or are the result of a 
protocol -specified intervention, including ,but not limited to washout or discontinuation of 
usual therapy, diet, placebo, or a procedure.
All nonserious AEs and other reportable safety events (excluding pregnancy and lactation 
exposure) must be reported by [CONTACT_93317] [ADDRESS_103104]:   V116  53
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103105] be reported by [CONTACT_93318]’s 
participation in the study, regardless of whether related to the study intervention .
Investigators are not obligated to actively seek AE sor SAEs or other reportable safety events 
in former study participants. Ho wever, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and the investigator 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3 .
Exception: A positive pregnancy test at the time of initial screening is not a reportable event 
unless the participant has received study intervention.
Table 3 Report ing Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol- specified 
Follow -up PeriodReporting Time 
Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame to 
Report Event 
and Follow -up 
Information to 
Sponsor:
NSAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is receiving 
placebo run -in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is receiving 
placebo run -in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
-any death until 
participant completion 
of study
(Follow ongoing to 
outcome)Within 24 hours 
of learning of 
event
Pregnancy/
Lactation ExposureReport if:
-participant has been 
exposed to any 
protocol- specified 
intervention (eg, 
procedure, washout or 
run-in treatment 
including placebo run -
in)
Exception: A positive 
pregnancy test at the 
time of initial screening 
is not a reportable 
event.Report all Previously reported –
Follow to completion/
termination; report 
outcomeWithin 24 hou rs 
of learning of 
event
ECI (require regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-Potential DILI
-Require regulatory 
reportingNot required Within [ADDRESS_103106]:   V116  54
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol- specified 
Follow -up PeriodReporting Time 
Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame to 
Report Event 
and Follow -up 
Information to 
Sponsor:
ECI (do not require 
regulatory reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs and 
those not requiring 
regulatory reportingNot required Within 5 calendar 
days of learning 
of event
Cancer Report if:
-due to intervention
-causes exclusi onReport all Not required Within 5 calendar 
days of learning 
of event
(unless serious)
Overdose Report if:
-receiving placebo run -
in or other run -in 
medication Report all Not required Within 5 calendar 
days of learning 
of event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse 
even t.
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial A E/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make every attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_93319] a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country -specific regulatory requirements and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and inv estigators.
Investigator safety reports must be prepared for S[LOCATION_003]R saccording to local regulatory 
requirements and Sponsor policy and forwarded to investigators as necessary.
08J3TW
PRODUCT:   V116  55
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
An investigator who receives an investigator safety report describing an SAE or o ther 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy.
Any pregnancy complication will be reported as an AE or SAE.
The medical reason (example: maternal health or fetal disease) for an elective termination of 
a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born 
with severe abnormalities/congenital anomalies that leads to an elective termination of a 
pregnancy will be reported as an SAE for the fetus.
Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth 
must be reported as serious events (Important Medical Events). If the pregnancy continues to 
term, the outcom e (health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable for this study.
8.4.[ADDRESS_103107]
There are no ECIs for this study .
8.4.8 Medical Device and Drug- device Combination Products -PQCs/Malfunctions
The method of documenting and reporting of such events (complaints associated with 
medical devices including PQCs/malfunctions) will occur as below and in Appendix 4. 
To fulfill regulatory reporting obligations worldwide, medical device information associated 
with AEs will be collected and reported to the Sponsor in the same time frame as AEs per
Section 8.4.1 via CRF (paper or electronic) and as per data entry guidelines.
PQCs/ma lfunctions including those that involve a participant or any user/associated person 
must be reported to the Sponsor. Sponsor shall review reported events by [CONTACT_93320] s and other entities 
about certain safety information relating to medical devices and drug- device combination 
products being used in clinical studies.
08J3TW
PRODUCT:   V116  56
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
The investigator is responsible for ensuring that follow- up includes any supplemental 
investigations as i ndicated to elucidate the nature and/or causality between the AE and the 
medical device or device constituent of combination product .
8.4.9 Adverse Events on the VRC
Participants will use a n eVRC to report solicited and unsolicited AEs.
The definitions of solicited and unsolicited AEs can be found in Appendix 3.
[IP_ADDRESS] Solicited Adverse Event
Solicited AEs for this study are summarized in Table 4.
Table 4 Solicited Adverse Events
Type of 
Solicited 
Adverse EventPredefined Solicited Adverse Events (Preferred 
Term)Solicited Time 
Period
Injection -site Injection -site pain or tenderness ( injection -site pain)
Injection -site redness ( injection -site erythema)
Injection -site swelling ( injection -site swelling)Day 1 through Day 5
postvaccination
Systemic Headache (headache)
Muscle aches all over body (myalgia)
Tiredness (fatigue)Day 1 through Day 5
postvaccination
[IP_ADDRESS] Unsolicited Adverse Events
Unsolicited AEs for this study are events that are 1) not predefined in Table 4, or 
2)predefined in Table 4but reported at any time outside of the solicited time period. 
8.[ADDRESS_103108]:   V116  57
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
8.8 Biomarkers
Biomarkers are not evaluated in this study.
8.9 Future Biomedical Research Sample Collection
If the participant provides documented informed consent for FBR , the following specime ns 
will be obtained as part of FBR :
•DNA for future research
•Leftover study serum after completion of immunogenicity testing ,stored for future 
research
8.10 Optional Assay Development Blood Sample Collection
If the participant documented informed consent for the optional assay development blood 
samples, these samples will be used to support future development work on improving 
bioanalytical measurements, which requires high- volume single -donor samples to monitor 
performance of the assay over time. 
Sample collection, storage, and shipment instructions for the optional assay development 
blood samples will be provided in the operations/laboratory manual.
8.11 Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics are not evaluated in this study.
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific proc edure -related details areprovided 
inSection 8.
8.12.1 Screening
Screening procedures will be conducted at Visit 1 as outlined in Section 1.3. Potential 
participants will be evaluated to determine that they fulfill the entry requirements as set forth 
in Section 5.
If Visit 1 is rescheduled (see Section 5.2), a pregnancy test (if applicable), a body 
temperature measurement , and a review of inclusion/exclusion criteria, prior 
medications/vaccinations, and medical history must be repeated before vaccination.
8.12.2 Treatment Period/Vaccination Visit
Requirements during the treatment period are outlined in Section 1.[ADDRESS_103109]:   V116  58
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103110] hoc exploratory 
analys es will be clearly identified in the CSR .
9.1 Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below ; the comprehensive plan 
is provided in Section 9.2 through Section 9.12
Study Design Overview A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and 
Immunogenicity of V116 in Pneumococcal Vaccine- Experienced Adults 50 
Years of Age or Older
Treatment assignment Cohort 1: P articipants wil lbe randomly assigned in a 2:1 ratio to receive V116
or PCV15 . Randomization will be stratified by [CONTACT_654] (50 to 64 , ≥65years of age) 
and time since pneumococcal vaccination (1 to 4, 5to 9, ≥10years )
Cohort 2: Participants will be randomly assigned in a 2:1 ratio to receive V116 
or PPSV23. Randomization will be stratified by [CONTACT_654] (50 to 64 , ≥65 years of 
age) and time since pneumococcal vaccination (1 to 4, 5to 9, ≥10years )
Cohort 3: Participants will receive V116 only
Analysis Populations Immunogenicity: PPpopulation
Safety : APaT population
Primary Endpoints Immunogenicity :
Serotype -specific OPA GMTs at30days postvaccination
Safety :
Proportion of participants with solicited injection -site AEs 
(redness/erythema, swelling, tenderness/pain) from Day 1 through Day 5 
postvaccination
Propo rtion of participants with solicited systemic AEs (muscle aches all over 
body/myalgia, headache, tired ness/fatigue) from Day 1 through Day 5
postvaccination 
Proportion of participants with vaccine -related SAEs from Day  1 through the 
duration of participation in the study
Key Secondary 
EndpointsSerotype -specific IgG GMCs at 30 days postvaccination
Statistical Methods for
Key Immunogenicity
AnalysesImmunogenicity analyses will be conducted separately for each serotype in 
V116 within each vaccination group in each cohort .To address the primary 
immunogenicity objective, evaluation of the OPA GMTs at30 days 
postvaccination in each cohort will include descriptive summaries and within -
group 95% CIs for each vaccination group.
Statistical Methods for
Key Safety Analyses For the overall safety evaluation, safety parameters will be summarized via 
descriptive statistics within each vaccination group in each cohort . For select 
safety parameters, point estimates and within -group 95% CIs will be provided by
[CONTACT_93321] .
08J3TW
PRODUCT:   V116  59
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103111] to enable a 
benefit risk asse ssment.
Multiplicity No multiplicity adjustment is planned as there is no hypothesis testing .
Sample Size and Power This is a descriptive study that consists of 3 cohorts, enrolling a total of 
approximately 700 participants . Cohort 1 will randomize 300 participants ; 200 
into the V116 group and 100 into the PCV15 group. Cohort 2 will randomize 300 
participants ; 200 into the V116 group and 100 into the PPSV23 group. Cohort 3 
will be comprised of 100 participants . It is assumed that 270 participants in 
Cohort 1 (180 in V116, 90 in PCV15), 270 participants in Cohort 2 (180 in V116, 
90 in PPSV23), and 90 participants in V116 in Cohort 3 will be evaluated for PP 
immunogenicity analyses at Day 30 for V116 (based on a 90% evaluability rate). 
There are no hypotheses to be evaluated , but Section 9.9.1 provides information 
about the expected variability of the OPA GMT s given the sample size.
9.2 Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the Sponsor.
This study is being conducted as a hybrid randomized and blinded, and nonrandomized open -
label study depending on each specific cohort. 
Cohorts 1 and 2 will be double -blind under in- house blinding procedures. The final database 
will not be unblinded until medical/scientific review has been performed, protocol deviations 
have been identified, and data have been declared final and complete.
Cohort 3 will be open -label. The participants, investigators, and Sponsor personnel will be 
aware of participant treatment assignments after each participant is enrolled and treatment is 
assigned. 
The Clinical Biostatistics department will generate the randomization schedule(s) forstudy 
intervention assignment. An IRT system will be used to allocate and/or randomize 
participants .
Blinding issues related to the planned interim analyses are described in Section 9.7.
9.3 Hypotheses/Estimation
Objectives of the study are stated in Secti on 3. This is an estimation study and no hypothesis 
testing will be performed.
9.[ADDRESS_103112]:   V116  60
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
9.4.1 Immunogenicity Endpoints
Immune responses will be assessed for each of the serotypes contained in V116: 3, 6A, 7F, 
19A, 22F, and 33F , 8, 9N, 10A, 11A, 12F, 17F, 20, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 
35B. Immune responses will also be assessed for 2 cross -reactive serotypes (6C and 15B).
For the primary and sec ondary immunogenicity endpoints, all serotypes in V116 will be 
assessed within each vaccination group in each cohort as follows:
Cohort 1: V116 and PCV15
o6 serotypes common to V116 and PCV15 (3, 6A, 7F, 19A, 22F ,and 33F)
o15serotypes unique to V116 (8, 9N , 10A, 11A, 12F, 15A, 15C, 16F, 17F, 20, 
23A, 23B, 24F, 31, and 35B )
Cohort 2: V116 and PPSV23
o12serotypes common to V116 and PPSV23 (3, 7F, 8, 9N, 10A, 11A, 12F, 
17F, 19A, 20, 22F, and 33F )
o9serotypes unique to V116 (6A, 15A, 15C, 16F, 23A, 23B, 24F, 31 , and 35B )
Cohort 3: V116
o21 serotypes in V116 ( 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F ,17F, 
19A, 20, 22F, 23A, 23B, 24F, 31, 33F , and 35B )
The primary immunogenicity endpoint include s:
Serotype- specific OPA GMTs at 30 days postvaccination
The secondary immunogenicity endpoints include:
Serotype -specific IgG GMCs at30 days postvaccination
Serotype -specific GMFR and proportion of participants with a ≥4 -fold rise from baseline
(Day 1) to [ADDRESS_103113]:   V116  61
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
9.4.2 Safety Endpoints
The safety endpoints for overall safety assessment that address the primary objectives
include:
Proportion of participants with solicited injection -site AEs (redness/erythema, swelling, 
and tenderness/pain) from Day  1 through Day 5 postvaccination
Proportion of participants with solicited systemic AEs (muscle aches all over 
body/myalgia, headache, and tiredness/fatigue) from Day  1 through Day 5 
postvaccination
Proportion of participants with vaccine -related SAEs from Day 1 through the duration of 
participation in the study
Additional safety endpoints for overall safety assessment include :
Proportion of participants with the broad AE categories consisting of any AE, any 
unsolicited AEs, and any vaccine -related AE from Day 1 through Day 30 postvaccination
in eac h cohort
Proportion of participants with the broad AE categories consisting of any SAE, any 
vaccine -related SAEs, and death from Day [ADDRESS_103114] AE category of 
discontinuation of study intervention due to an AE is not applicable
Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day 1 through Day 5 postvaccination in each 
cohort
9.5 Analysis Populations
9.5.1 Immunogenicity Analysis Populations
The PP population will serve as the primary population for the analysis of immunogenicity 
data in this study. The PP population consists of all allocated/ randomized participants 
without deviations from the protocol that may substantially affect the results of the 
immunogenicity endpoints. Potential deviations that may result in the exclusion of a 
participant from the PP population for all immunogenicity analyses include:
Failure to receive study vaccine at Visit 1(Day 1)
Failure to receive correct clinical material as per randomization schedule 
Failure to receive pneumococcal vaccine ≥[ADDRESS_103115]:   V116  62
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Receipt of a prohibited medication or prohibited vaccine prior to study vaccination
Additional potential deviations that may result in the exclusion of a participant’s 
measurement from a specific time point assessment in the PP population for immunogenicity 
analyses include:
Receipt of a prohibited medication or prohibited vaccine prior to a blood sample 
collection
Collec tion of a blood sample outside of the prespecified window 
For each cohort, t he final determination on protocol deviations , and thereby [CONTACT_93322], will be made prior to the final unblinding of the database andwill be 
documented in a separate memo . Participants will be included in the vaccination group to 
which they are randomized for the analysis of immunogenicity data using the PP population.
A supportive analysis using the FAS population will also be performed for the primary 
immunogenicity endpoint. The FAS population consists of all randomized participants who 
received study vaccination and have at least 1 serology result. Participants will be i ncluded in 
the vaccination group to which they are randomized for the analysis of immunogenicity data 
using the FAS population.
9.5.2 Safety Analysis Populations
Safety analyses will be conducted in the APaT population, which consists of all 
randomized/allocated participants who received at least [ADDRESS_103116] study vaccination ; such participants will be included in the group corresponding to 
the study vaccination actually received. If a participant receives a study vaccine that does not 
belong to the assigned cohort, (eg, a participant from Cohort 1 receives PPSV23 , or a 
participant from Cohort 2receives PCV15 ), this participant will be excluded from the APaT
population. For Cohort 3, if a participa nt receives an incorrect study vaccination, this 
participant will be excluded from the APaT population. The safety data for participants 
excluded from the APaT population will be summarized separately .
At least 1temperature measurement obtained subsequent to study intervention is required for 
inclusion in the analys is of temperature .
9.[ADDRESS_103117]:   V116  63
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
9.6.1 Statistical Methods for Immunogenicity Analyses
This section describes the statistical methods that address the primary and secondary 
immunogenicity objectives. Methods related to exploratory objectives will be described in 
the sSAP .
Immunogenicity analyses will be conducted for each of the 21 pneumococcal serotypes 
included in V116. To address the primary immunogenicity objective, the evaluation of the 
OPA GMTs at 30 days postvaccination will include descriptive summaries and within -group 
95% C Is.
To address the secondary immunogenicity objective s, the evaluation of the IgG GMCs at 
30days postvaccination will include descriptive summaries and within -group 95% C Is.
Additionally, the GMFRs and proportions of participants with a ≥4 -fold rise from baseline 
for both OPA and IgG responses will include descriptive summaries and within -group 95% 
CIs at30 days postvaccination. For the continuous endpoints, the point estimates will be 
calculated by [CONTACT_93323] -group CIs will be derived by [CONTACT_93324] s based on the t -distribution. For the dichotomous endpoints, the within -
group CIs will be calculated based on the exact method proposed by [CONTACT_93325]
[CLOPPER, C. J. and PEARSON, E. S. 1934] .
Reverse C umulative Distribution Curves for OPA titers and IgG concentrations will be 
graphically displayed by [CONTACT_93326] .A detailed analysis strategy for immunogenicity endpoints 
is listed in Table [ADDRESS_103118]:   V116  64
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Table 5 Analysis Strategy for Immunogenicity Variables
Endpoint/Variable
(Description, Time Point)Primary vs 
Supportive 
ApproachaStatistical MethodAnalysis 
PopulationMissing Data 
Approach
Primary Endpoint
OPA GMTs at30 days postvaccination PDescriptive Statistics
(estimate, 95% CI)PP Missing data 
will not be 
imputed S FAS
Secondary Endpoints
IgG GMCs at30 days postvaccination PDescriptive Statistics
(estimate, 95% CI) PPMissing data 
will not be 
imputed
GMFR and proportion of participants 
who achieved a ≥4 -fold rise from 
baseline (Day 1) to 30 days 
postvaccination for both OPA and IgG 
responsesPDescriptive Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed
CI=confidence interval ; FAS= full analysis set; GMC= geometric mean concentration; GMFR= geometric mean 
fold rise; GMT= geometric mean titer; IgG=immunoglobulin G; OPA=opsonophagocytic activity; PP= per-
protocol .
a P=primary approach; S=supportive approach.
9.6.2 Statistical Methods for Safety Analyses
Safety and tolerability will be assessed by [CONTACT_14339], 
including AEs and postvaccination temperature measurements.
[IP_ADDRESS] Overall Safety Assessment
The overall safety evaluation will include a summary (ie, number and percentage) of 
participants with any AEs , any unsolicited AEs, anyvaccine -related AEs, anySAEs , any
vaccine -related SAEs, and anyAEsresulting in death postvac cination in each cohort . Point 
estimates and within -group 95% CIs forthe percentages of participants with the event will be 
provided for these events .
The number and percentage of participants with specific AEs will also be provided. Point 
estimates and within -group 95% CIs for the percentages of participants with specific AEs 
will be provided for solicited AEs and AEs that occur in ≥5% of participants across 
vaccination groups .
The number and percentage of participants with maximum temperature measurements 
catego rized by [CONTACT_93327] [Marcy, S. M., et al 2004] will be provided 
along with point estimates and within -group 95% CIs to evaluate elevated temperatures.
08J3TW
PRODUCT:   V116  65
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Within -group CIs will be calculated using the Clopper Pearson method [CLOPPER, C. J. and 
PEARSON, E. S. 1934] . CIs should only be regarded as helpful descriptive measures for the 
review of the safety profile and not as a for mal method for assessing statistical significance.
The analysis strategy for safety endpoints in this study are summarized in Table 6.
Table 6 Ana lysis Strategy for Safety Parameters
Analysis Part Safety EndpointDescriptive 
StatisticsWithin -group
95% CI
Overall 
Safety 
AssessmentSolicited injection -site AE (Day 1 through Day 5 postvaccination )aX X
Solicited systemic AE (Day 1 through Day 5 postvaccination )aX X
Any AEbX X
Any unsolicited AEbX X
Any vaccine -related AEbX X
Any SAEbX X
Any vaccine -related SAEbX X
DeathbX X
Specific AEs by [CONTACT_93328] X
Maximum temperatures (Day 1 through Day 5postvaccination )dX X
AE=adverse event; CI= confidence interval ; PT= preferred term; SAE=serious adverse event; SOC= system organ class .
aSolicited injection -site AEs include redness/erythema, swelling, and tenderness/pain; solicited systemic AEs include 
muscle aches all over body/myalgia, headache, and tiredness/fatigue.
bThese endpoints are broad AE categories. For example, descriptive statistics for the safety endpoint of “Any AE” will 
provide the number and percentage of participants with at least 1 AE.
cWithin each cohort, descriptive s tatistics will be provided for specific AEs with incidence >0% of participants in any
vaccination group; additionally w ithin-group 95% CIs will be provided for specific AEs with incidence ≥5% of 
participants in any vaccination group .
dMaximum temperature measurements are categorized by [CONTACT_93327].
9.6.3 Demographic and Baseline Characteristics
The comparability of the vaccination groups in each cohort for each relevant demographic 
and baseline characteristic will be assessed by [CONTACT_93329]. No statistical 
hypothesis tests will be performed on these characteristics. The number and percentage of 
participants screened and randomized and the primary reasons for screening failure and 
discontinuation will be displayed. Demographic variables (eg, age, race, ethnicity, sex, and 
gender ), baseline characteristics, and prior and concomitant vaccinations and therapi[INVESTIGATOR_93272].
9.[ADDRESS_103119]:   V116  66
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103120] to enable a benefit risk assessment.
The DMC will serve as the primary reviewer of the results of the ongoing safety reviews and 
will make recommendations for continuation of the study (with or without protocol 
modifications ) or discontinuation of the study to an executive oversight committee of the 
Sponsor (see Appendix 1 for details on the Committees Structure for this study). If the DMC 
recommends modifications to the design of the protocol or discontinuation of the study, the 
oversight committee (and potentially other limited Sponsor personnel) may be unblinded to 
results at the intervention level to act on these recommendations. The extent to which 
individuals are unblinded with respect to ongoing safety reviews will be documented by [CONTACT_93330]. Additional logistical details will be provided in the DMC 
Charter.
Study enrollment may be ongoing at the time of external DMC review. 
For all cohorts, ongoing safety reviews will be provided by [CONTACT_93331] .For Cohorts 1 and 2, blinding to study intervention assignment will be 
maintained at all investigational sites. Participant -level unblinding will be restric ted to an 
external unblinded statistician performing ongoing safety reviews. Prior to final study 
unblinding ,the external unblinded statistician will not be involved in any discussions 
regarding modifications to the protocol, statistical methods, identifi cation of protocol 
deviations, or data validation efforts after the safety reviews.
9.8 Multiplicity
No multiplicity adjustment is planned as there is no hypothesis testing.
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
This is a descriptive study that consists of 3 cohorts, enrolling a total of approximately 700 
participants. Cohort 1 will randomize 300 participants (200 into the V116 group and 100 into 
the PCV15 group ), Cohort 2 will randomize 30 0 participants (200 into the V116 group and 
100 into the PPSV23 group ), and Cohort 3 will be comprised of 100 participants who will all 
be allocat ed to receive V116. It is assumed that 270 participants in Cohort 1 (180 in the V116
group and 90 in the PCV15 group ), 270 participants in Cohort 2 (180 in the V116 group and
90 in the PPSV23 group ), and 90 participants in Cohort 3 will be evaluated for PP 
immunogenicity analyses at Day 30 (based on a 90% evaluability rate). 
The width of the within -group 95% CIs for the serotype -specific OPA GMTs depend on the 
sample size, variability of the natural log concentrations, and the magnitude of the OPA 
GMT. The 95% CIs for various hypothetical OPA GMTs and various hypothetical standard 
deviation estimates for the natur al log titers are displayed in Table [ADDRESS_103121]:   V116  67
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Table 7 Within -group 95% CIs for Varying Hypothetical OPA GMTs and Varying 
Standard Deviations
Standard 
Deviation 
of Natural 
Log TitersaSerotype -specific OPA GMTa
500 1000 5000
Evaluable 
ParticipantsbN=90 N=180 N=90 N=180 N=90 N=180
1.0 (406, 616) (432, 579) (811, 1233) (863, 115 8) (4055 , 6165) (4316, 57 92)
1.5 (365, 685) (401, 623) (730, 1369) (802, 1247) (3652 , 6846) (4010, 6 234)
2.0 (329, 760) (373, 671) (658, 1520) (745, 1342) ( 3289 , 7601 ) (3726, 6 710)
2.5 (296, 844) (346, 722) ( 592, 1688) ( 692, 1444) ( 2962 , 8441 ) (3462 , 7222)
CI=confidence interval; GMT=geometric mean titer; OPA=opsonophagocytic activity.
a The estimates of the standard deviation and OPA GMTs arerepresentative of those observed in V116 -001.
bThe sample size sare based on the evaluable participants per vaccination group in each cohort .
9.9.[ADDRESS_103122] 1 SAE in this study depends on the 
number of participants vaccinated and the underlying incidence of participants w ith a SAE in 
the study population. Calculations below assume that 100% of the enrolled participants will 
be evaluable for safety analyses. 
For Cohorts 1 and 2, t here is an 80% chance of observing at least 1 SAE among 
200participants if the underlying incidence of a SAE is 0.80% (1 of every 124participants 
receiving the vaccine). There is a 50% chance of observing at least 1 SAE among 
200participants if the unde rlying incidence of a SAE is 0.35% (1 of every 289participants 
receiving the vaccine). If no SAEs are observed among the 200participants, this study will 
provide 97.5% confidence that the underlying percentage of participants with a SAE is 
<1.83% (1 in e very 54participants).
For Cohort 3, t here is an 80% chance of observing at least 1 SAE among 100participants if 
the underlying incidence of a SAE is 1.60% (1 of every 62 participants receiving the 
vaccine). There is a 50% chance of observing at least 1 S AE among 100 participants if the 
underlying incidence of a SAE is 0.69% (1 of every 144 participants receiving the vaccine). 
If no SAEs are observed among the 100 participants, this study will provide 97.5% 
confidence that the underlying percentage of participants with a SAE is < 3.62% (1 in every 
27participants).
08J3TW
PRODUCT:   V116  68
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
9.10 Subgroup Analyses
Serotype -specific OPA GMTs and their corresponding 95% CIs will be calculated within 
each vaccination group for each subgroup of the following classification variables :
•Age category ( 50 to 64, ≥65 years)
•Sex 
•Race
•Ethnicity 
•Time since prior pneumococcal vaccination (1 to 4, 5 to 9, ≥10 years )
•For Cohort 3: prior pneumococcal vaccination history (PCV 15, P CV20, 
PCV13+PPSV23, PCV15+PPSV23, PPSV23+ PCV13)
In addition, a summary of AEs and a summary of solicited AEs will be provided for each of 
the subgroups listed above (point estimates only ).
The subgroup analyses will be performed within each cohort separately.
Further details of subgroup analyses will be documented in the sSAP .
9.11 Compliance (Medication Adherence)
Given that the participants will receive a single dose of V116 or PCV15 in Cohort 1, V116 or 
PPSV23 in Cohort 2, or V116 in Cohort 3 , compliance will not be calculated .However, the 
number and proportion of randomized participants receiving each vaccination will be 
summarized by [CONTACT_9084] (Section 9.12).
9.[ADDRESS_103123]:   V116  69
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_103124] for Clinical Trials
[COMPANY_006] Sharp &Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted 
in compliance with local and/or national regulations (including all applicable data protection laws and
regulations), and International Counci l for Harmonisation Good Clinical Practice (ICH -GCP), and also in 
accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventio nal investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator- initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trial s to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where 
applicable, third parties . All trial protocols are and will be assessed for the need and capability to enroll 
underrepresented groups. Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD ’s clinical trials are conducted globally in many different countries and in diverse populations, including 
people of varying age, race, ethnicity, gender, and accounting for other potential disease related factors. MSD 
selects investigative sites based on medical ex pertise, access to appropriate participants, adequacy of facilities 
and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial initiation, 
sites are evaluated by [CONTACT_26397] (or individuals acting on behalf of MSD) to assess the ability to 
successfully conduct the trial.
Where appropriate, and in accordance with regulatory authority guidance, MSD will make concerted efforts 
to raise awareness of clinical trial opportunities in various communities. MSD will seek to engage 
08J3TW
PRODUCT:   V116  70
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
underrepresented groups and those disproportionately impacted by [CONTACT_26398]. MSD will support 
clinical trial investigators to enroll underrepresented groups and expand access to those who will ultimately 
use the products under inves tigation.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verifie d versus 
source documentation according to standard operating procedures. Per MSD policies and procedures, if
potential fraud, scientific/research misconduct, privacy incidents/breaches orClinical Trial -related 
Significant Quality Issues are reported, such matters are investigated . When necessary, appropriate corrective 
and/or preventative actions are defined and regulatory authorities and /orethics review committees are 
notified.
B. Publi cation and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the recommendations published by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethic s 
Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, proto col amendment(s), informed consent form, investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. 
MSD will inform regulatory authorities of such new measures to protect participant safety, in c ompliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as a lternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants ma y withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible , as well as all 
applicable data protection rights . Unless required by [CONTACT_2371], only the investigator, Sponsor (or individuals acting on 
08J3TW
PRODUCT:   V116  71
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records 
that might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_88709].
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. Howeve r, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on cha rt review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by [CONTACT_19487], and that the investigator or sponsoring 
institution is being paid or provi ded a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial d isclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor ’s responsibility to determine, based on these regulations, whether a request for 
financial d isclosure information is required. It is the investigator ’s/subinvestigator ’s 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/ Disclosure Form, frequent ly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the
transmission of information to countries that do not have laws protecting personal data.
08J3TW
PRODUCT:   V116  72
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103125] this study in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be info rmed that his/her personal study- related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by [CONTACT_88710] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affir ms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an app ropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or c opy study documents to 
verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified by u nique code only; full 
names/initials will be masked before transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable priva cy laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496] .
08J3TW
PRODUCT:   V116  73
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.1.4 Committees Structure
[IP_ADDRESS] Executive Oversight Committee
The EOC is comprise d of members of Sponsor Senior Management. The EOC will receive 
and decide on any recommendations made by [CONTACT_93332].
[IP_ADDRESS] External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they cannot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study.
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of the study. A lso, the DMC will review interim 
study results, consider the overall risk and benefit to study participants ( Section 9.7) and 
recommend to the EOC whether the study should continue in accordance with the protocol.
Specific details regarding composition, re sponsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
[IP_ADDRESS] Scientific Advisory Committee (SAC)
This study was developed in collaboration with a SAC . The SAC is comprise d of both 
Sponsor and non -Sponsor scient ific experts who provide input with respect to study design, 
interpretation of study results, and subsequent peer -reviewed scientific publications.
10.1.[ADDRESS_103126]:   V116  74
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study is solely responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltria ls.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trials directive mandated trials . 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_88712]- site contact [CONTACT_3031].
By [CONTACT_12570], the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive ,or other locally mandated registries are that of the 
Sponsor and agrees not to submi t any information about this study or its results to those 
registries.
10.1.[ADDRESS_103127] the study in an efficient and 
diligent manner and in conformance with this protoco l; generally accepted standards of G CP
(eg, I CH GCP: Consolidated Guideline and other generally accepted standards of GCP ); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical study.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inf orm the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations re sulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened .
08J3TW
PRODUCT:   V116  75
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, labor atory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management procedures for this protocol will be
provided separately.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying , review, and audit at reasonable times by [CONTACT_19502]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review an d verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in acc ordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants’ documented informed consent , pertaining to 
the conduct of this study must be re tained by [CONTACT_1732] 15 years after study 
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No rec ords may be transferred to another location or party without written 
notification to the Sponsor .
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator /institution should maintain adequate and 
accurate source documents and study records that include al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate , and complete. Changes to source data should be 
08J3TW
PRODUCT:   V116  76
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available .
10.1.10 Study and Site Closure
The Sponsor or its designee may stop the study or study -site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s).
08J3TW
PRODUCT:   V116  77
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in will be performed by [CONTACT_12082].
•Protocol -specific requirements for inclusion or exclusion of particip ants are detailed in 
Section 5of the protocol.
•Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
Table 8 Protocol -require d Safety Laboratory A ssessments
Laboratory 
Assessments Parameters
Pregnancy 
Testing•Highly sensitive serum or urine hCG pregnancy test (as needed for 
WOCBP)
hCG=human chorionic gonadotropin ;WOCBP=women of childbearing potential
The i nvestigator (or medically qualified designee) must document their review of each 
laboratory safety report.
08J3TW
PRODUCT:   V116  78
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.[ADDRESS_103128].
10.3.2 Defini tion of AE
AE definition
•An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•Note: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
•Note: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine, diagnostic 
agent, medical device, combination product, or protocol specified procedure whether 
investigational or marketed (including placebo, active comparator product, or run-in 
intervention) , manufactured by, licensed by, provided by, or distributed by [CONTACT_88715].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent preexi sting condition including either an 
increase in frequency and/or intensity of the condition.
08J3TW
PRODUCT:   V116  79
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug- drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with a n associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adv erse effect.”
•Any new cancer or progression of existing cancer.
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
•Surgical procedure(s) planned prior to informed consent to treat a preexisting condition 
that has not worsened.
•Refe r to Section 8.4.6 for protocol -specific exceptions.
Definition of Unsolicited and Solicited AE
•An unsolicited AE is an AE that was not solicited using a VRC and that is communicated 
by a participant/participant’s legally authorized representative who has signed the 
informed consent. Unsolicited AEs include serious and nonserious AEs.
•Solicited AEs are predefined local (at the injection/administration site) and systemic 
events for which the participant/participant’s legally authorized representative is 
specifically questioned, and which are noted by [CONTACT_2299]/participant’s legally 
authorized representative in their VRC.
10.3.[ADDRESS_103129]:   V116  80
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103130] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_10240]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a preexisting condi tion that has not 
worsened is not an SAE. )A preexisting condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
d.Results in persistent or significant disability/incapacity
•The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immed iately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered se rious.
•Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
08J3TW
PRODUCT:   V116  81
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.3.4 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.5 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the A E/SAE.
Assessment of i ntensity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of overall intensity grade for each AE and SAE 
(and other reportable event) reported dur ing the study. An overall intensity grade will be 
assigned to injection- site AEs, specific systemic AEs, other systemic AEs, and vital sign 
(temperature) AEs as shown in the following tables. The overall intensity grading scales 
used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 
Clinical Trials, September 2007” [Food and Drug Administration 2007] .
08J3TW
PRODUCT:   V116  82
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Injection -Site AE Overall Intensity Grading Scale
Injection -Site 
Reaction to Study 
Vaccine/PlaceboMild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially Life -
Threatening
(Grade 4)
Injection -site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo
Pain/Tenderness Does not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_2666]/Redness Size measured as
≤5cmSize measured as
5.1to 10 cmSize measured as
>10cmNecrosis or 
exfoliative 
dermatitis or 
results in ER visit 
or hospi[INVESTIGATOR_93273] 
≤5cmSize measured as
5.1to 10 cmSize measured as
>10cmNecrosis or ER 
visit or 
hospi[INVESTIGATOR_93274]-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63479] -site reaction that begins ≥6 days after receipt of study vaccine/placebo
Pain/Tenderness
Erythema/Redness
Swelling
OtherDoes not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93275]=adverse event; ER=emergency room; eVRC=electronic Vaccine Report Card
Theoverall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food 
and Drug Administration 2007] .
08J3TW
PRODUCT:   V116  83
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Specific Systemic AE Overall Intensity Grading Scale
Systemic (General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life -
Threatening
(Grade 4)
Headache No interference 
with activityRepeated use of non -
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use 
of narcotic pain 
reliever or prevents 
daily activityER visit or 
hospi[INVESTIGATOR_93276]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93277]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93278]=emergency room
The overall intensity grading scales used in this study are adap ted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food 
and Drug Administration 2007] .
Other Systemic AE Overall Intensity Grading Scale
Systemic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life -
Threatening
(Grade 4)b
Illness or clinical AE 
(as defined 
according to 
applicable 
regulations)No interference 
with activitySome interference 
with activity not 
requiring medical 
interventionPrevents daily 
activity and 
required medical 
interventionER visit or 
hospi[INVESTIGATOR_93275]=adverse event; ER=emergency room; eVRC=electronic Vaccine Report Card; SAE=serious adverse event
The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food 
and Drug Administration 2007] .
aBased upon information provided by [CONTACT_63555] -up period. For SAEs reported beyond th e primary safety follow -up period, grading will be based upon the 
initial report and/or follow -up of the event.
bAEs resulting in death will be assessed as Grade 4.
08J3TW
PRODUCT:   V116  84
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Vital Sign (Temperature) Overall Intensity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life -
Threatening
(Grade 4)
Fever (°C)b
(°F)b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.0
The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food 
and Drug Administration 2007] .
aParticipant should be at rest for all vital sign requirements.
bOral temperature; no recent hot or cold beverages or smoking.
Assessment of c ausality
•Did the Sponsor’s product cause the AE?
•The determination of the likelihood that the Sponsor’s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assess ing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor’s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the 
Sponsor’s product such as: reliable history, acceptabl e compliance assessment 
(diary, etc.), seroconversion or identification of vaccine virus in bodily specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor’s product? Is the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors?
-Rechallenge: Was the participant re -exposed to the Spons or’s product in the study?
◦If yes, did the AE recur or worsen?
◦If yes, this is a positive rechallenge.
◦If no, this is a negative rechallenge.
08J3TW
PRODUCT:   V116  85
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose vaccine study; or (3) 
Sponsor’s product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370]’S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPON SOR’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY [CONTACT_93333], AND IF REQUIRED, THE 
IRB/IEC.
•Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor’s product or drug class 
pharmacology or toxicology?
•The assessment of relationship will be reported on the CRFs/worksheets by [CONTACT_26368] a qualified physician according to their best clinical judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor’s product relationship).
-Yes, there is a reasonable possibility of Sponsor’s product relationship:
◦There is evidence of exposure to the Sponsor’s product. The temporal sequence 
of the AE onset relative to the administration of the Sponsor’s product is 
reasonable. The AE is more likely explained by [CONTACT_19457]’s product than by 
[CONTACT_5748].
-No, there is not a reasonable possibility of Sponsor’s product relationship:
◦Participant did not receive the Sponsor’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor’s product is not reasonable 
OR the AE is more likely explained by [CONTACT_26372]’s 
product. (Also entered for a participant with overdose without an associated 
AE.)
•The investigator must review and provide an assessment of causality for each AE/SAE 
and document this in the medical notes.
•There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assess ment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change their opi[INVESTIGATOR_9242]- up information 
and send an SAE follow- up report with the updated causality assessmen t.
08J3TW
PRODUCT:   V116  86
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
•The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.6 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
•The primary mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
◦Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or recei ves updated data 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
08J3TW
PRODUCT:   V116  87
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
•In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_93334] a copy of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames .
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent) .
08J3TW
PRODUCT:   V116  88
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.4 Appendix 4: Medical Device and Drug- device Combination Products : Product 
Quality Complaints/Malfunction s: Defin ition s, Recording, and Follow -up
The recording and follow -up procedures described in this protocol apply to all medical 
devices as described below. For purposes of this section, medical devices in scope for device 
information collection include devices int ended to be used by a study participant according to 
the study protocol, that are manufactured by [CONTACT_88716] a third party, 
licensed by [CONTACT_88717]/or drug -device combination products as listed in 
Section 6.1.1. Product Quality Complaints/Malfunctions must be reported to the Sponsor.
10.4.[ADDRESS_103131] comprised of two or more regulated components (ie, a 
drug and a device; a biologic and device; a biologic and a drug; or a drug, a device, and a 
biologic ). Combination products can be single entity, copackaged, or colabeled.
Complaint -Any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliability, safety, effectiveness, or per formance of a device 
after it is released for distribution. This would include PQC, AE, and customer feedback.
A complaint does not necessarily need to involve a user or any other person. 
Constituent Part -A drug, device, or biological product that is pa rt of a combination 
product.
Customer Feedback - Areport that does not allege a PQC or defect and has no relevant 
safety information/untoward event associated with it (eg, goodwill or courtesy replacement, 
consumer preference or suggestion, remark which may suggest an improvement in the 
functionality or quality of a medical device or dev ice-like features of a drug delivery system).
Malfunction -The failure of a device to meet its performance specifications or otherwise 
perform as intended.
Medical Device - Any instrument, apparatus, appliance, material or other article, whether 
used alone or in combination, including the software necessary for its proper application 
intended by [CONTACT_88718]: 
•diagnosis, preventi on, monitoring, treatment or alleviation of disease, 
•diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap, 
•investigation, replacement or modification of the anatomy or of a physiological process,
•control of conception, 
08J3TW
PRODUCT:   V116  89
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103132] identified by [CONTACT_88721]. This includes 
potential device or device component malfunctions. Note: Areport of Lack or Limited 
Efficacy is considered an AE rather than a PQC .
Serious Injury -An injury or illness that: 
Is life -threatening, 
Results in permanent impairment of a body function or permanent damage to a body 
structure, or 
Necessitates medical or surgical intervention to preclude permanent impairment of a 
body fu nction or permanent damage to a body structure.
Permanent means irreversible impairment or damage to a body structure or function, 
excluding trivial impairment or damage.
10.4.2 Recording, Assessing Causality, and Follow -up of PQC s/Malfunctions
Recording
•When a C omplaint including PQC/malfunction occurs it is the responsibility of the 
investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, 
and diagnostic reports) related to the event .
•Events occurring during the study will be recorded in the participant’s medical records, in 
accordance with the investigator’s normal clinical practice, and on the appropriate CRF 
(paper or electronic) as per instructions provided in the data entry guidelines . Medical 
device/device constituent par t of drug device combination product information will be 
collected and reported to the Sponsor in the same time frame as SAEs as per Section 
8.4.1 via CRF (paper or electronic) . PQCs/malfunctions must be reported to the Sponsor .
Assessing Causality
•A“reas onable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship.
•The investigator will use clinical judgement to determine the relationship.
•Alternative causes such as underlying disease(s), concomitant ther apy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration should be considered and investigated.
08J3TW
PRODUCT:   V116  90
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Follow -up
•The investigator will perform or arrange for the conduct of supplemental mea surements 
and/or evaluations as medically indicated or as requested by [CONTACT_88722]/or causality of the event as complete as possible.
08J3TW
PRODUCT:   V116  91
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of st udy intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilat eral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for [ADDRESS_103133]:   V116  92
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only contraceptive implantc
•IUSd
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method 
of contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoos permia for a male participant can come from the site personnel’s review of 
the participant’s medical records, medical examination, or medical history interview.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly.
•Combined (estrogen -and progestogen -containing) hormonal contraceptionc
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptionc
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation t o the duration of the study and the preferred and usual 
lifestyle of the participant.
Methods That Are Not Considered Highly Effective
Failure rate of >1% per year when used consistently and correctly.
•Progesterone- only hormonal contraception where inhibition of ovulation is not the primary mode of action
•Male or female condom with or without spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double 
barrier methods) .
aContraceptive use by [CONTACT_93335].
bTypi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly).
cIf locally required, in accordance with CTFG guidelines, acceptable hormonal contraceptives are limited to those which 
inhibit ovulation. 
dIUS is a progestin releasing IUD.
Note: The following are not acc eptable methods of contraception:
-Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and LAM.
-Male and female condom should not be used together (due to risk of failure with frict ion).
Country -specific contraception requirements are included in Appendix 7.
08J3TW
PRODUCT:   V116  93
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition .1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research3, 4
The specimens consented and/or collected in this study as outlined in Section 8. 9will be 
used in various experiments to understand:
• The biology of how drugs/va ccines work
• Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
• Other pathways with which drugs/vaccines may interact
• The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultima tely 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
3.Summary of Procedures for Future Biomedical Researc h3, [ADDRESS_103134]:   V116  94
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during
screening for protocol enrollment from all participants or legal guardians, at a study 
visit by [CONTACT_63559] d esignate. Informed consent for future 
biomedical research should be presented to the participants on the visit designated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_88723].
A template of each study site’s approved informed consent wi ll be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional blood specimens ar e being collecte d for future 
biomedical research, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research3, 4
In order t o optimize the resea rch that can be conducted with future biomedical research
specimens, it is critical to link participant s' clinical information with future test results. In 
fact,little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like sex, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical research
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
08J3TW
PRODUCT:   V116  95
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103135] party (eg, a university investigator) designated by [CONTACT_429]. The investigator conducting the analysi s will follow the Sponsor’s privacy and 
confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope o f analysis outlined in future biomedical research protocol and consent . 
Future biomedical research specimens remai ning with the third party after specific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Biomedical Research3, [ADDRESS_103136] the Sponsor using the designated mailbox 
(clinical.specimen.management@ MSD .com). Subsequently, the participant's specimens 
will be flagged in the biorepository and restricted to study use only. If specimens were 
collected from study participants specifically for FBR, these specimens will be removed 
from the biorepository and destroyed. Documentation will be sent to the investigator 
confirming withdrawal and/or destruction, if applicable. It is the responsibility of the 
investigator to inform the participant of completion of the withdrawal and/or destruction, 
if applicable. Any analyses in progress at the time of request for withdrawal/destruction 
or already performed before the request being received by [CONTACT_93336]. No new analyses would be 
generated after the request is r eceived.
If the medical records for the study are no longer available (eg, if the investigator is no 
longer required by [CONTACT_88692]) or the specimens 
have been completely anonymized, there will no longer be a link between the 
participant’s personal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens3, [ADDRESS_103137]:   V116  96
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103138] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants3, 4
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: l ack of relevance to participant health, limitations of predictive 
capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make r esults accessible on a public website in order to
rapi[INVESTIGATOR_88651]. Participants will not be 
identified by [CONTACT_88726].
10. Future Biomedical Research Study Population3, [ADDRESS_103139] security, policies, and procedures to address participant 
data privacy concerns. Data p rivacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to th e future biomedical research should be e mailed directly to 
clinical.specimen.management@ MSD .com.
08J3TW
PRODUCT:   V116  97
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Council on Harmoni sation [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Availa ble from 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/definitions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry Pharmacogenomics Working Group [Internet]: Understanding t he Intent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
08J3TW
PRODUCT:   V116  98
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.7 Appendix 7: Country -specific Requirements
10.7.1 Country -specific Requirements for Japan
Section 5.2 Exclusion Criteri on
For study sites in Japan, to comply with current Japan national guidance , the following 
criterion replaces Exclusion Criterion 10 in Section 5.2:
1.*Received any nonlive vaccine ≤14 days before receipt of study vaccine or is scheduled 
to receive any nonlive vaccine ≤30 days after rec eipt of any study vaccine. Exception : 
inactivated influenza vaccine may be administered but must be given ≥7 days before or 
≥15days after receipt of study vaccine. SARS -CoV -[ADDRESS_103140] be given ≥14 days before or ≥[ADDRESS_103141] (s) (MSD marketed/MSD investigation medicinal product 
and medical device or non- MSD marketed/non -MSD investigational product and medical 
device) provided for use in this study are: V116 prefilled syringes, VAXNEUVANCE™ 
prefilled syring es,and PNEUMOVAX™23 prefilled syringes . Refer to below for instruction 
on reporting events associated with these devices.
Appendix 4: Medical Device and Drug -device Combination Products: Product Quality 
Complaints/Malfunctions: Definitions, Recording, an d Follow -up
The recording and follow -up procedures described in this protocol apply to all medical 
devices /combination medicinal products as described below. For purposes of this section, 
medical devices/combination medicinal products in scope for device information collection 
include devices/combination medicinal products intended to be used by a study participant 
according to the study protocol, that are manufactured by [CONTACT_88716] a 
third party, licensed by [CONTACT_88717]/or drug -device combination products, 
as listed above. Product quality complaints/malfunctions must be reported to the Sponsor.
10.4.1 Definitions
Medical Device -Devices, etc (other than regenerative medicine products) intended for use 
in the diagnosis, treatment or prevention of disease in humans or animals, or intended to 
affect the structure or functions of the body of humans or animals.
Combination Medicinal Product -A product comprised of two or more regulated 
components, i e, a drug and a device; a device and a cellular and tissue -based products; a 
cellular and tissue -based products and a drug; or a drug, a device, and a cellular and tissue -
based products according to Japan regulations.
08J3TW
PRODUCT:   V116  99
PROTOCOL/AMENDMENT NO.:   [ADDRESS_103142] sense such as damage or operational failure.
Serious Adverse Event due to Malfunction -Any SAE due to malfunction in the 
characteristics and/or performance of a device (this study includes pre-filled syringe s)as well 
as any inadequacy in the labeling or the instructions for use which might lead to or might 
have led to the death of a participant and/or the associated person or to a serious deterioration 
in their state of health.
Malf unction Which may L ead to Serious Adverse Events -Any malfunction of a medical 
device which might have led to the death of a participant and/or the associated person or to a 
serious deterioration in their state of health. “Which might have led to” means t hat there is 
the possibility that death or a serious deterioration might have occurred in a participant 
and/or the associated person, although these cases have not actually occurred .
10.4.2 Medical Device/Combination Medicinal Products –Documenting and Re porting
In order to fulfill Japan regulatory reporting obligations, medical device/combination 
medicinal product information will be collected. SAEs due to malfunction will be reported to 
the Sponsor in the same time frame as SAEs as per Section 8.4.1 via CRF (pap er or 
electronic) and as per data entry guidelines. All SAEs due to malfunction will be followed 
until resolution, stabilization, until the event is otherwise explained, or the participant or 
associated person is lost to follow- up. Malfunction which may le ad to SAEs will be reported 
to the Sponsor within 5 calendar days of learning of the information via a paper reporting 
form .
Sponsor shall review reported events by [CONTACT_93337]/combination medicinal products being used in 
clinical studies.
10.4.3 Recording, Assessing Causality, and Follow -up of Adverse Events due to 
Malfunctions (s erious and nonserious)
Recording
•When AEs due to malfunctions (serious or nonserious) occurs, it is the responsibility of 
the investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory 
reports, and diagnostic reports) related to the event.
•Any AEs due to malfunctions (serious or nonserious) occurring during the study will be 
recorded in the participant’s medical records, in accordance with the investigator’s 
normal clinical practice, and on the appropriate CRF (paper or electronic) as per 
instructions in the EDC data entry guidelines (or equivalent).
•It is important that the investigator provides anassessment of causality (relationship to 
the medical device) at the time of the initial report.
08J3TW
PRODUCT:   V116  100
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Assessing Causality
•A “reasonable possibil ity” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship.
•The investigator will use clinical judgment to determine the relationship.
•Alternative causes should also be considered and investigated, such as underlying 
disease(s), concomitant therapy, and other risk factors as well as the temporal relationship 
of the event to study intervention administration.
Follow -up
•The investigator will perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_93338]/or causality of the event as fully as possible.
10.7.[ADDRESS_103143] Exclusion Criteri a9 and 1 0in 
Section 5.2:
9. Receiv edimmunosuppressive therapy within 6 months before vaccination , including 
chemotherapeutic agents or other immunotherapi[INVESTIGATOR_014]/immunomodulators used to treat 
cancer or other conditions, and interventions associated with organ or bone marrow 
transplantation, or autoimmune disease.
10. * Received any nonlive vaccine ≤15days before receipt of study vaccine or i s scheduled 
to receive any nonlive vaccine ≤30 days after receipt of any study vaccine. Exception : 
inactivated influenza vaccine andSARS -CoV -[ADDRESS_103144] be given ≥15 days before or after receipt of study vaccine .
To clarify the exclusion criteria for protected populations, the following criterion is 
added to Section 5.2:
17. Adults protected by [CONTACT_28769], persons deprived of their liberty by a judicial or administrative 
decision, those hospi[INVESTIGATOR_93279], and persons admitted to a health or social 
institution for purposes other t han research.
08J3TW
PRODUCT:   V116  101
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Section 6.5 Concomitant Therapy
For study sites in [LOCATION_009], to clarify and align with the [LOCATION_009] -specific exclusion criteri a
above, the following concomitant therapy replaces the original one in Section 6.5:
Medications or vaccinations speci fically prohibited in the exclusion criteria are not allowed 
during the ongoing study (Section 10.7.2 ). If there is a clinical indication for any medications 
or vaccinations specifically prohibited, discontinuation from study intervention may be 
required. The investigator should discuss any questions regarding this with the Sponsor 
Clinical Director. The final decision on any supportive therapy or vaccination rests with the 
investigator and/or the participant’s primary physician. However, the decision to co ntinue the 
participant on study intervention requires the mutual agreement of the investigator, the 
Sponsor, and the participant.
It is important to record the use of any analgesic or antipyretic medication that occurs on the 
day of vaccination on the eVRC and appropriate eCRF.
Listed below are specific restrictions for concomitant therapy or vaccination:
•Administration of a nonstudy pneumococcal vaccine is prohibited during the study.
•Nonstudy vaccines may only be administered before or after the receipt of study vaccines 
according to the time frames specified in the Exclusion Criteria (Section 5.2).
•Receipt of systemic corticosteroids (prednisone equivalent ≥20 mg/day) for ≥14 
consecutive days is prohibited from 14 days before vaccination through 30 days 
following vaccination. Note : physiologic replacement doses (prednisone equivalent of 
approximately 5 mg/day), topi[INVESTIGATOR_2855], ophthalmic, intraarticular or soft -tissue (eg, bursa, 
tendon steroid injections), and inhaled/nebulized steroids are permitted.
•Receipt of immunosuppressive therapy within 6 months before vaccination, including 
chemotherapeutic agents or other immunotherapi[INVESTIGATOR_014]/immunomodulators used to treat 
cancer or other conditions, and interventions associated with organ or bone marrow 
transplantation, or autoimmune disease.
•Receipt of a blood transfusion or blood products, including immunoglobulin ≤[ADDRESS_103145] -vaccination blood draw is complet e. Autologous blood 
transfusions are not considered an exclusion criterion.
•Receipt of any nonlive vaccine ≤15 days before receipt of study vaccine or is scheduled 
to receive any nonlive vaccine ≤30 days after receipt of any study vaccine. Exception: 
inact ivated influenza vaccine and SARS -CoV -[ADDRESS_103146] be given ≥15 days before and after receipt of study vaccine.
•Receipt of any live virus vaccine ≤30 days before receipt of study vaccine or is scheduled 
to receive any live virus vaccine ≤[ADDRESS_103147]:   V116  102
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant manageme nt.
Use of prior and concomitant medications/vaccinations should be recorded as described in 
Section 8.1.5.
Section 10.5.2 Contraception Requirements
For study sites in [LOCATION_009], to clarify the contraception method sallowed during the 
study, the following ta ble replaces Contraception Requirements in Section 10.5.2:
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only subdermal contraceptive implantc
•IUSd
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method 
of contraception should be used. A spermatogenesis cycle is approximately 90 day s.
Note: Documentation of azoospermia for a male pa rticipant can come from the site personnel’s review of 
the participant’s medical records, medical examination, or medical history interview. 
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistent ly and correctly .
•Combined (estrogen -and progestogen -containing) hormonal contraceptionc
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptionc
-Oral
-Injectable
08J3TW
PRODUCT:   V116  103
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and th e preferred and usual 
lifestyle of the participant.
aContraceptive use by [CONTACT_93339].
bTypi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and 
correctly).
cIf locally required, in accordance with CTFG guidelines , acceptable hormonal contraceptives are limited 
to those which inhibit ovulation.
dIUS is a progestin releasing IUD .
Note: The following are not acceptable methods of contraception:
-Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus 
interruptus), spermicides only, and LAM.
-Male and female condom should not be used together (due to risk of failure with friction ).
08J3TW
PRODUCT:   V116  104
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
ABCs Active Bacterial Core Surveillance
ACIP Advisory Committee on Immunization Practices
AE adverse event 
APaT All-Participants -as-Treated
C polysaccharide capsular polysaccharide
CDC Centers for Disease Control and Prevention
CFR Code of Federal Regulations
CI confidence interval
CONSORT Consolidated Standards of Reporting Trials
CRF Case Report Form 
CSF cerebrospi[INVESTIGATOR_93280]-O-acylated
DMC Data Monitoring Committee 
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECI event of clinical interest
ECL electrochemiluminescence
eCRF electronic Case Report Form
EDC electronic data collection 
EEA European Economic Area
EMA European Medicines Agency
EOC Executive Oversight Committee 
EU European Union
eVRC electronic Vaccination Report Card
FAS Full Analysis Set
FBR Future Biomedical Research
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act
FSR First Site Ready
GCP Good Clinical Practice 
GMCs geometric mean concentrations
GMFR geometric mean fold rise
GMTs geometric mean titers
hCG human chorionic gonadotropin
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB Investigator’s Brochure 
ICF Informed Consent Form
08J3TW
PRODUCT:   V116  105
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Abbreviation Expanded Term
ICH International C ouncil for Harmoni sation of Technical Requirements 
for Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IgG Immunoglobulin G
IHC immunohistochemistry
IM intramuscular(ly)
IMP investigational medicinal product
IND Investigational New Drug 
IPD invasive pneumococcal disease
IRB Institutional Review Board
IRT interactive response technology
IUD intrauterine device
IUS intrauterine hormone -releasing system
LAM lactational amenorrhea method
MOPA Multiplexed Opsonophagocytic Assay
mRNA messenger RNA
NIMP noninvestigational medicinal product
OPA opsonophagocytic activity
PCV pneumococcal conjugate vaccine
PCV7 PREVNAR ™
PCV13 pneumococcal 13 -valent conjugate vaccine , PREVNAR 13™
PCV15 pneumococcal 15- valent conjugate vaccine ,VAXNEUVANCE™ 
(Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 
and 33F)
PCV20 pneumococcal 20- valent conjugate vaccine , PREVNAR 20™
(Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 
18C, 19A, 19F, 22F, 23F, and 33F)
PnECL pneumococcal electrochemiluminescence
PnPs pneumococcal polysaccharide
PP per-protocol
PPSV23 pneumococcal vaccine, polyvalen t (23- valent) , PNEUMOVAX™23 
(Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19 A, 19F, 20, 22F, 23F, and 33F)
PQC product quality complaint
RNA ribonucleic acid
SAC Scientific Advisory Committee
SAE serious adverse event 
SARS -CoV -[ADDRESS_103148](s)
SoA schedule of activities
sSAP supplemental Statistical Analysis Plan
S[LOCATION_003]R suspected unexpected serious adverse reaction
US [LOCATION_002]
VRC Vaccination Report Card
08J3TW
PRODUCT:   V116  106
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
Abbreviation Expanded Term
WOCBP woman/women of childbearing potential
08J3TW
PRODUCT:   V116  107
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
11 REFERENCES
[Anttila, M., et al 1999] Anttila M, Voutilainen M, Jäntti V, Eskola 
J, Käyhty H. Contribution of serotype -
specific IgG concentration, IgG subclasses 
and relative antibody avidity to 
opsonophagocytic activity against 
Streptococcus pneumoniae. Clin Exp 
Immunol 1999;118(3):402- 7.[03QY70]
[Burton, Robert L. and Nahm, 
Moon H. 2006]Burton RL, Nahm MH. Development and 
validation of a fourfold mu ltiplexed 
opsonization assay (MOPA4) for 
pneumococcal antibodies. Clin Vaccine 
Immunol 2006;13(9):1004- 9.[03QT2R]
[Centers for Disease Control 
and Prevention 2010]Centers for Disease Control and 
Prevention. Prevention of Pneumococcal 
Disease Among Infan ts and Children - Use 
of 13- Valent Pneumococcal Conjugate 
Vaccine and 23 -Valent Pneumococcal 
Polysaccharide Vaccine; 
Recommendations of the Advisory 
Committee on Immunization Practices 
(ACIP). MMWR 2010;59(RR -11):1- 19.[03RSB6]
[Centers for Disease Contro l 
and Prevention 2015]Centers for Disease Control and 
Prevention. Epi[INVESTIGATOR_93281] -preventable diseases. 13th ed. 
Hamborsky J, Kroger A, Wolfe S, editors. 
Washington (DC): Department of Health 
and Human Services (HHS); c2015. 
Chapter 6, Vaccine administration; p. 79-
106.[0508PV]
[Centers for Disease Control 
and Prevention 2019]Centers for Disease Control and 
Prevention. Advisory Committee on 
Immunization Practices (ACIP), summary 
report, October 24- 25, 2018. Washington 
(DC): Depart ment of Health and Human 
Services (HHS); 2019. 190 p.[057YZL]
08J3TW
PRODUCT:   V116  108
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
[Centre for Disease Control 
and Prevention 2016]Centre for Disease Control and Prevention. 
Active Bacterial Core surveillance (ABCs) 
report emerging infections program 
network Streptococcus pneumoniae, 2016. 
Atlanta (GA): Department of Health and 
Human Services (HHS); 2016. 1 p.[052RDB]
[Centre for Disease Control 
and Prevention 2018]Centers for Disease Control and 
Prevention. Active Bacterial Core 
surveillance (ABCs) report: emerging 
infections program network: Streptococcus 
pneumoniae, 2018. Washington (DC): 
Department of Health and Human Services 
(HHS); 2018.[05J8JP]
[CLOPPER, C. J. and 
PEARSON, E. S. 1934]Clopper CJ, Pearson ES. The use of 
confidence of fiducial limits illustrated in 
the case of the binomial. Biometrika 
1934;26(4):404- 13.[03RRVC]
[Curcio, D., et al 2015] Curcio D, Cane A, Isturiz R. Redefining 
risk categories for pneumococcal disease 
in adults: critical analysis of the evidence. 
Int J Infect Dis. 2015; 37:30 -5.[04VSHL]
[Demczuk, W. H. B., et al 
2013]Demczuk WHB, Martin I, Griffith A, 
Lefebvre B, McGeer A, Lovgren M, et al. 
Serotype distribution of invasive 
Streptococcus pneumoniae in Canada after 
the introduction of the 13 -valent 
pneumococcal conjugat e vaccine, 2010 -
2012. Can J Microbiol 2013;59:778 -88.[03XKZ6]
[Drijkoningen, J. J 2014] Drijkoningen JJ, Rohde GG. 
Pneumococcal infection in adults: burden 
of disease. Clin Microbiol Infect. 2014 
May;[ADDRESS_103149] 5:45- 51.[04NFHN]
[European Center for Disease 
Prevention and Control 2018]European Center for Disease Prevention 
and Control. Surveillance report: annual 
epi[INVESTIGATOR_93282] 2016: invasive 
pneumococcal disease. Stockholm 
(Sweden): European Center for Disease 
Prevention and Control (ECD C) 2018 
Aug. 12 p.[052RH8]
08J3TW
PRODUCT:   V116  109
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
[Food and Drug 
Administration 2007]Food and Drug Administration. Guidance 
for industry: toxicity grading scale for 
healthy adult and adolescent volunteers 
enrolled in preventive vaccine clinical 
trials. Rockville, MD. Sep 2007 .[05B4S4]
[Golden, A. R., et al 2016] Golden AR, Adam HJ, Zhanel GG. 
Invasive Streptococcus pneumoniae in 
Canada, 2011- 2014: Characterization of 
new candidate 15- valent pneumococcal 
conjugate vaccine serotypes 22F and 33F. 
Vaccine. 2016 May 17;34(23):252 7-30.[04KWF0]
[Hicks, L. A., et al 2007] Hicks LA, Harrison LH, Flannery B, 
Hadler JL, Schaffner W, Craig AS, et al. 
Incidence of Pneumococcal Disease Due 
to Non- Pneumococcal Conjugate Vaccine 
(PCV7) Serotypes in the [LOCATION_002] 
during the Era of Wides pread PCV7 
Vaccination, [ADDRESS_103150] Dis 
2007;196:1346- 54.[03QT0G]
[Janssens, J. P. 2004] Janssens JP, Krause KH. Pneumonia in the 
very old. Lancet Infect Dis. 2004 
Feb;4:112 -24.[04VTNJ]
[Kobayashi, M. 2021] Kobayashi M. Considerations for age -
based and risk- based use of PCV15 and 
PCV20 among U.S. adults and proposed 
policy options. Slides presented at: 
Advisory Committee on Immunization 
Practices (ACIP) meeting; [ADDRESS_103151] 20 -
21; Atlanta, GA.[07XY2V]
[Kobayashi, M., et al 2022] Kobayashi M, Farrar JL, Gierke R, Britton 
A, Childs L, Leidner AJ, et al. Use of 15 -
valent pneumococcal conjugate vaccine 
and 20- valent pneumococcal conjugate 
vaccine among U.S. adults: updated 
recommendations of the Advisory 
Committee on Immunizati on Practices -
[LOCATION_002], 2022. MMWR Morb Mortal 
Wkly Rep. 2022 Jan 28;71(4):109 -17.[07YPRJ]
08J3TW
PRODUCT:   V116  110
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
[Kyaw, M. H., et al 2005] Kyaw MH, Rose CE, Jr., Fry AM, 
Singleton JA, Moore Z, Zell ER, et al. The 
influence of chronic illnesses on the 
incidence of invasi ve pneumococcal 
disease in adults. J Infect Dis 
2005;192(3):377 -86.[03QTFW]
[Marcy, S. M., et al 2004] Marcy SM, Kohl KS, Dagan R, Nalin D, 
Blum M, Connell Jones M, et al. Fever as 
an adverse event following immunization:  
case definition and guidelines of data 
collection, analysis, and presentation. 
Vaccine 2004;22:551- 6.[03PVW0]
[Matanock, A. 2018] Matanock A. Estimating pneumococcal 
pneumonia burden among U.S. adults and 
progress on the research agenda for 
potential policy change. Slides presented 
at: Advisory Committee on Immunization 
Practices (ACIP) Meeting; 2018 Feb 21 -
22; Atlanta, GA.[05B5W5]
[Matanock, A., et al 2019] Matanock A, Lee G, Gierke R, Kobayashi 
M, Leidner A, Pi[INVESTIGATOR_63466] T. Use of 13 -
valent pneumococcal conjugate vaccine 
and 23- valen t pneumococcal 
polysaccharide vaccine among adults aged 
greater than or equal to 65 years: updated 
recommendations of the Advisory 
Committee on Immunization Practices. 
MMWR Morb Mortal Wkly Rep. 2019 
Nov 22;68(46):1069 -75.[05D5ST]
[Miller, Elizabeth, et al 2011] Miller E, Andrews NJ, Waight PA, Slack 
MP, George RC. Herd immunity and 
serotype replacement 4 years after seven-
valent pneumococcal conjugate 
vaccination in England and Wales: an 
observational cohort study. Lancet Infect 
Dis 2011;11(10):760 -8.[03RKY7]
08J3TW
PRODUCT:   V116  111
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
[Moore, M. R., et al 2015] Moore MR, Link- Gelles R, Schaffner W, 
Lynfield R, Lexau C, Bennett NM, et al. 
Effect of use of 13 -valent pneumococcal 
conjugate vaccine in children on invasive 
pneumococcal disease in children and 
adults in the [LOCATION_003]: analysis of multisite, 
population -based surveillance. Lancet 
Infect Dis. 2015 Feb 3. [Epub ahead of 
print].[043MRP]
[Nuorti, J. P. and Whitney, C. 
G. 2010]Nuorti JP, Whitney CG. Prevention of 
pneumococcal disease among infants and 
children  use of 13- valent pneumococcal 
conjugate vaccine and 23 -valent 
pneumococcal polysaccharide vaccine -
recommedations of the advisory 
committee on immunization practices 
(ACIP). MMWR 2010;59(R11):1 -19.[03RSLZ]
[Pi[INVESTIGATOR_63466], T. 2015] Pi[INVESTIGATOR_63466] T, Bennett NM. Pneumococcal 
disease prevention among adults: 
strategies for the use of pneumococcal 
vaccines. Am J Prev Med. 2015 Dec;49([ADDRESS_103152] 4):S383- 90.[04WP9S]
[Pi[INVESTIGATOR_63466], Tamara, et al 
2010]Pi[INVESTIGATOR_63466] T, Lexau C, Farley MM, Hadler 
J, Harrison LH, Bennett NM, et a l. 
Sustained reductions in invasive 
pneumococcal disease in the era of 
conjugate vaccine. J Infect Dis 
2010;201(1):32- 41.[03R5S4]
[Robert Koch Institut 2017] Robert Koch Institut. Statement of the 
German Standing Committee on 
Vaccination at the RKI: recommendations 
of the Standing Committee on Vaccination 
(STIKO) at the Robert Koch Institute -
2017/2018. Epid Bull. 2017 Aug 
24;(34):333- 76.[05MFT7]
08J3TW
PRODUCT:   V116  112
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
[Romero -Steiner, S., et al 
1997]Romero- Steiner S, Libutti D, Pais LB, 
Dykes J, Anderson P, Whitin JC, et al. 
Standardization of an opsonophagocytic 
assay for the measurement of functional 
antibody activity against streptococcus 
pneumoniae using differentiated HL- 60 
cells. Clin Diagn Lab Immunol 
1997;4(4):415- 22.[03NWQ5]
[Simonsen, L., et al 2014] Simonse n L, Taylor RJ, Schuck -Paim C, 
Lustig R, Haber M, Klugman KP. Effect 
of 13- valent pneumococcal conjugate 
vaccine on admissions to hospi[INVESTIGATOR_307] 2 years 
after its introduction in the [LOCATION_003]: a time 
series analysis. Lancet Respir Med. 2014 
May;2(5):387- 94.[04KVRV]
[Troeger, C., et al 2018] Troeger C, Blacker BF, Khalil IA, Rao 
PC, Cao S, Zimsen SRM, et al. Estimates 
of the global, regional, and national 
morbidity, mortality, and aetiologies of 
lower respi[INVESTIGATOR_93283] 195 
countries, 1990 -2016: a systematic 
analysis for the Global Burden of Disease 
Study 2016. Lancet Infect Dis. 2018 
Nov;18:1191- 210.[07XTBZ]
[U.S. Food and Drug 
Administration 2009]U.S. Food and Drug Administration 
(CDER, CBER, CDRH). Guidance for 
industry patient -reported outcome 
measures: use in medical product 
development to support labeling claims 
[Internet]. Washington: U.S. Department 
of Health and Human Services; 2009. 
Available from: 
https://www.fda.gov/downloads/drugs/gui
dances/ucm193282.pdf[04MG9J]
[van der Linden, M., et al 
2015]van der Linden M, Falkenhorst G, 
Perniciaro S, Imohl M. Effects of infant 
pneumococcal conjugate vaccination on 
serotype distribution in invasive 
pneumococcal disease among children and 
adults in [LOCATION_013]. PLoS One. 2015 Jul 
1;10(7):e0131494.[04KVRY]
08J3TW
PRODUCT:   V116  113
PROTOCOL/AMENDMENT NO.:   006 -02  
V116 -006-02FINAL PROTOCOL 06-JUL-2022
[van Hoek, A. J., et al 2012] van Hoek AJ, Andrews N, Waight PA, 
Stowe J, Gates P, George R, et al. The 
effect of underlying clinical conditions on 
the risk of developi[INVESTIGATOR_93284]. J Infect. 
2012 Jul;65(1):17- 24.[04NKDG]
[Waight, P. A., et al 2015] Waight PA, Andrews NJ, Ladhani SN, 
Sheppard CL, Slack MP, Miller E. Effect 
of the 13 -valent pneumococcal conjugate 
vaccine on invasive pneumococcal disease 
in England and Wales 4 years after its 
introduction: an observa tional cohort 
study. Lancet Infect Dis. 2015 
May;15(5):535 -43.[04KTF2]
[Weycker, D., et al 2010] Weycker D, Strutton D, Edelsberg J, Sato 
R, Jackson LA. Clinical and economic 
burden of pneumococcal disease in older 
US adults. Vaccine 2010;28(31):4955- 60.[03RFMJ]
08J3TW